Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study

Beyond stroke therapy, neuroaid (a chinese... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/13-799" }, "headline": "Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric...", "datePublished": "2024-07-16T12:29:56", "dateModified": "2025-09-18T14:47:11", "author": [ { "@type": "Person", "name": "ARMAN YURISALDI SALEH" }, { "@type": "Person", "name": "Riezky Valentina" }, { "@type": "Person", "name": "Tirta Darmawan Susanto" }, { "@type": "Person", "name": "Dwi Arwandi Yogi Saputra" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": " Introduction NeuroAiD, also known as MLC601 or MLC901, is a Chinese herbal combination used worldwide for stroke treatment. It contains herbal components and five hewan components. MLC601 contains herbal components and hewan components, while MLC901 has a similar herbal composition. NeuroAiD is used to support neurologic recovery after stroke and to aid cognitive function in Alzheimer’s disease. Studies show that NeuroAiD has potential in treating Alzheimer’s disease and is beneficial in both local and global stroke models and in the Kortikal culture. However, there is limited bibliometric research on NeuroAiD, which is a method of collecting data from published articles to analyze developments and trends in the field of research. This research contributes significantly to the literature and helps develop more effective stroke treatment strategies. Methods In this work, a literature review methodology is employed to gather data from the Scopus database using the keywords neuroaid. Data were analyzed using Biblioshiny and VOSviewer software to produce visualizations and bibliometric maps. We conducted quantitative and qualitative analysis Results The research trend found are documents by year, most relevant sources, factorial map of the most cited documents, factorial map of The documents with the highest contributes, documents by author, documents by country or territory, documents by subject area, documents by affiliation, network visualization, overlay visualization of scopus database using vosviewer, density visualization, thematic map, thematic evolution, topic dendogram, and world cloud. Conclusions The study investigates the potential of Neuroaid, a neuroprotective drug, for stroke prevention and cognitive function enhancement. It uses terms like “cognition” and “neurogenesis” to highlight its potential. While the study’s focus may be limited, it provides valuable insights into research direction and potential areas of neuroaid for stroke treatment. " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/13-799/v2", "name": "Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on..." } } ] } Home Browse Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article SALEH AY, Valentina R, Susanto TD and Saputra DAY. Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] . F1000Research 2025, 13 :799 ( https://doi.org/10.12688/f1000research.152581.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Systematic Review Revised Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] ARMAN YURISALDI SALEH https://orcid.org/0000-0001-5866-3585 1 , Riezky Valentina 1 , Tirta Darmawan Susanto https://orcid.org/0000-0002-4151-5946 2 , Dwi Arwandi Yogi Saputra 3 ARMAN YURISALDI SALEH https://orcid.org/0000-0001-5866-3585 1 , Riezky Valentina 1 , Tirta Darmawan Susanto https://orcid.org/0000-0002-4151-5946 2 , Dwi Arwandi Yogi Saputra 3 PUBLISHED 18 Sep 2025 Author details Author details 1 Neurology Department Faculty of Medicine, UPN Veteran Jakarta, Jakarta, Special Capital Region of Jakarta, 12450, Indonesia 2 Family Medicine and Primary Care, Universitas Pelita Harapan, Tangerang, Banten, 15811, Indonesia 3 Department of Public Health Sciences, Faculty of Medicine, UPN Veteran Jakarta, Jakarta, Special Capital Region of Jakarta, 12450, Indonesia ARMAN YURISALDI SALEH Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation Riezky Valentina Roles: Writing – Review & Editing Tirta Darmawan Susanto Roles: Validation, Writing – Review & Editing Dwi Arwandi Yogi Saputra Roles: Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Introduction NeuroAiD, also known as MLC601 or MLC901, is a Chinese herbal combination used worldwide for stroke treatment. It contains herbal components and five hewan components. MLC601 contains herbal components and hewan components, while MLC901 has a similar herbal composition. NeuroAiD is used to support neurologic recovery after stroke and to aid cognitive function in Alzheimer’s disease. Studies show that NeuroAiD has potential in treating Alzheimer’s disease and is beneficial in both local and global stroke models and in the Kortikal culture. However, there is limited bibliometric research on NeuroAiD, which is a method of collecting data from published articles to analyze developments and trends in the field of research. This research contributes significantly to the literature and helps develop more effective stroke treatment strategies. Methods In this work, a literature review methodology is employed to gather data from the Scopus database using the keywords neuroaid. Data were analyzed using Biblioshiny and VOSviewer software to produce visualizations and bibliometric maps. We conducted quantitative and qualitative analysis Results The research trend found are documents by year, most relevant sources, factorial map of the most cited documents, factorial map of The documents with the highest contributes, documents by author, documents by country or territory, documents by subject area, documents by affiliation, network visualization, overlay visualization of scopus database using vosviewer, density visualization, thematic map, thematic evolution, topic dendogram, and world cloud. Conclusions The study investigates the potential of Neuroaid, a neuroprotective drug, for stroke prevention and cognitive function enhancement. It uses terms like “cognition” and “neurogenesis” to highlight its potential. While the study’s focus may be limited, it provides valuable insights into research direction and potential areas of neuroaid for stroke treatment. READ ALL READ LESS Keywords neuroaid, cognitive enhancement, stroke, neuroprotective, bibliometric Corresponding Author(s) ARMAN YURISALDI SALEH ( [email protected] ) Close Corresponding author: ARMAN YURISALDI SALEH Competing interests: No competing interests were disclosed. Grant information: The author(s) declared that no grants were involved in supporting this work. Copyright: © 2025 SALEH AY et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: SALEH AY, Valentina R, Susanto TD and Saputra DAY. Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] . F1000Research 2025, 13 :799 ( https://doi.org/10.12688/f1000research.152581.2 ) First published: 16 Jul 2024, 13 :799 ( https://doi.org/10.12688/f1000research.152581.1 ) Latest published: 18 Sep 2025, 13 :799 ( https://doi.org/10.12688/f1000research.152581.2 ) Revised Amendments from Version 1 We added a few changes in the Introduction and Methods sections. We added a few changes in the Introduction and Methods sections. See the authors' detailed response to the review by Christopher Li Hsian Chen See the authors' detailed response to the review by Ping-Chung Leung READ REVIEWER RESPONSES Introduction NeuroAiD, also known as MLC601 or MLC901, is a combination of traditional Chinese herbs that has been used widely throughout the world for stroke therapy. 1 , 2 NeuroAiD contains nine herbal plants that help in blood circulation. 1 NeuroAiD (MLC601 and MLC901) is a drug derived from traditional Chinese medicine. Both formulations have herbal components, but there are differences in their composition. MLC601 (NeuroAiD) MLC601 consists of nine herbal components and five animal components. The herbal components include: Radix astragali, Radix salviae miltiorrhizae, Radix paeoniae rubra, Rhizoma chuanxiong, Radix angelicae sinensis, Carthamus tinctorius, Prunus persica, Radix polygalae, and Rhizoma acori tatarinowii. Animal components in MLC601 include Hirudo, Eupolyphaga seu steleophaga, Calculus bovisartifactus, Buthus martensii, and Cornu saigae tataricae. 3 MLC901 (NeuroAiD II) MLC901 is a simplified version of MLC601 and contains only the same nine herbal components as MLC601. 1 , 4 Both forms have demonstrated neuroprotective and neurodegenerative effects in cerebral ischemia models. 3 , 5 However, MLC901 has several advantages that may improve patient compliance. 6 Although MLC601 and MLC901 have similar safety and efficacy profiles, MLC901 does not contain animal components, which makes it more acceptable to patients who may have objections to the use of animal products. 6 This drug has been used extensively to facilitate neurological recovery after stroke, especially in the non-acute phase. Additionally, NeuroAiD has also been used to support cognitive function in Alzheimer’s disease. Clinical and preclinical studies suggest that NeuroAiD has a role in Alzheimer’s disease. Additionally, NeuroAiD has demonstrated neuroprotective and neuroregenerative properties in animal models of focal and global ischemia as well as in cortical cell cultures. These properties are critical in developing treatment strategies to reduce long-term disability from stroke, heart attack, and other brain injuries. Although NeuroAiD has been widely researched, no bibliometric studies have been conducted using documents from www.scopus.com . Bibliometric studies are a research method that uses data from scientific publications to analyze developments and trends in a particular research field. In this context, bibliometric studies can provide valuable insight into NeuroAiD research and how its use has evolved over time. This research is especially important as there is increasing research on NeuroAiD and an increasing number of neurology centers using NeuroAiD for stroke therapy. Apart from that, this research also aims to look at the possibility of using NeuroAiD as a standard stroke therapy in the future. Thus, this study hopes to make a significant contribution to the existing literature and assist in the development of more effective stroke treatment strategies. Objectives This study aims to: 1. Analyze publication trends, geographic distribution, and institutional contributions in NeuroAiD research from 2008 to 2024. 2. Identify the most prolific authors, journals, and subject areas associated with NeuroAiD. 3. Map thematic evolution and keyword clusters using bibliometric tools such as Biblioshiny and VOSviewer. Methods Bibliometric research is a research method that uses scientific publication data to describe and analyze the development of a field of science. This research aims to identify and map trends, patterns, and relationships between scientific documents related to certain topics. In this research, the topic chosen was neuroaid. This research uses data from the website www.scopus.com , which is one of the largest and most trusted databases for scientific publications. This research was conducted on early May 2024. To carry out bibliometric research, the steps to follow are as follows: 1. Determine search keywords. In this research, the keywords used are neuroaid. These keywords are entered into the search column on the www.scopus.com site by selecting the topic field (title, abstract, keywords). 2. Filter search results. In this study, Were not filtered. 3. Download search results data. In this research, search result data is downloaded in three different formats, namely: • CSV (comma-separated value), which contains basic information about the document, such as title, author, affiliation, year, source, abstract, and keywords. • RIS (research information system), which contains detailed information about a document, including the references cited by the document. Data for this study were collected by one reviewer. Reviewers work independently in collecting data from each report. To ensure data accuracy and clutter. In addition, we use automated tools, namely the *VosViewer* and *Biblioshiny* applications, to assist in the data collection and analysis process. In this study we found are documents by year has been an increase in the number of documents; until 2023, there were 9 documents, most relevant sources is journal of cerebrovascular diseases, documents by author with the most authors with 30 documents are Venketasubramanian, N., documents by country or territory is singapore is the country with the largest number of document producers 37 documents, documents by subject area, network visualization, overlay visualization of scopus database using vosviewer, density visualization, thematic map based on the title shows that the niche theme is the keyword mitochondria signaling pathway, effects neuroprotective effect, dan oxidative stres toxicity, thematic evolution, cluster analysis, qualitative analysis, and word cloud. This review does not follow the “living” systematic review format. Instead, it represents a one-time bibliometric snapshot based on predefined inclusion criteria and a transparent search strategy. We have clarified this distinction in both the title and the Methods section to avoid misinterpretation. Data collection We used the following terms to do a search on the Scopus website, taking into consideration that this website contains research that is considered to be valid: TITLE – ABS – KEY (neuroaid) are the titles of the products that are under consideration. Ninety-two documents were received by us. We then save the document from Scopus in the form of a file with the extension.csv file following this step. Data analysis Both the Biblioshiny and Vosviewer software packages were utilised in the analysis process. Quantitative analysis Documents by year Based on Figure 1 , it appears that there has been an increase in the number of documents, until in 2023 there were 9 documents. The oldest document in 2008 was entitled Neuroaid in stroke recovery., written by Siow, C.H.C., 7 Next is the article entitled Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients written by Gan, R. et al. 8 Meanwhile, the latest document in 2024 is entitled Facilitation of neurological recovery in a complete spinal cord injury with NeuroAiD: case report written by Zainudin, M.F., Abu Hassan, S.A., Khin, N.Y. 9 Figure 1. Documents by year. Most relevant sources Based on Figure 2 , The following are the journals that publish the most important documents: The first is the Journal of Cerebrovascular Diseases. This journal is indexed in Scopus and is published by Karger Publisher. The SJR (SCImago Journal Rank) of this journal for 2023 is around 0.25. In 2023, this journal will be in the Q2 quartile for the cardiology and cardiovascular medicine category. The head office of Karger Publishers is located in Switzerland. The journal accepts manuscripts on topics covering prevention, diagnosis, management, rehabilitation, and related fields of molecular genetics, vascular biology, pathophysiology, epidemiology, and health systems science. The journal welcomes original research, reviews, and commentary articles focused on improving knowledge and information about clinical practice and health policy. The review time for this journal until the first decision is around 16.2 days. The H-index of this journal is 119. And the impact factor of this journal is around 2.96 in 2023. Figure 2. Most relevant sources. The next journal is the International Journal of Stroke. This journal is indexed in Scopus and published by SAGE Publications Ltd. The SJR (SCImago Journal Rank) for 2023 is around 1,952. As of 2023, the journal is in the Q1 quartile for the categories “Neurology” and “Neurology (clinical). The head office of SAGE Publications is located in the United Kingdom. The journal accepts manuscripts on topics covering clinical aspects of stroke from around the world with basic scientific contributions in the field of clinical interest. This journal accepts reviews of current topics, leading opinions, research, panoramas, clinical trial protocols, and guidelines. The time for this journal’s review to the first decision is around 15.0 days from this journal, which is around 6,948 in 2023. The next journal is the Stroke Journal. This journal has been indexed in Scopus since 1970. This journal is published by the American Heart Association. The SJR (SCImago Journal Rank) for 2023 is around 2,746. In 2023, this journal will be in the Q1 quartile for the categories Advanced and Specialized Nursing, Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), Neurology (clinical), and Neuroscience (miscellaneous). The headquarters of the American Heart Association are located in the United States. The journal accepts manuscripts on topics covering all aspects of cerebral circulation and its diseases from many disciplines, including neurology, internal medicine, radiology, nuclear medicine, neuropathology, neurosurgery, epidemiology, vascular surgery, rehabilitation, anesthesiology, critical care, vascular physiology, neuropsychology, speech pathology, and neuro-ophthalmology. The H-index of this journal is 357. And the impact factor of this journal is around 10.17 in 2023. Factorial map of the most cited documents Based on Figure 3 , the document with the most citations based on factorial analysis is The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES) by Chen CLH, Ikram K, Anqi Q, Yin WT, Chen A, and Venketasubramanian N, which was published in Cerebrovasc Dis in 2013. 10 , 11 Figure 3. Factorial map of the most cited documents. This article discusses the NEURITES study, a 24-week, double-blind, randomized, placebo-controlled phase II study of NeuroAiD II in patients with vascular cognitive impairment (VCIND). The aim of this study was to investigate the effects and tolerability of NeuroAiD II in patients with VCIND. 11 NeuroAiD is a traditional Chinese medicine that has been shown to induce neuroplasticity, stimulate cell proliferation, and stimulate the development of dense axial and dendritic tissue in animal stroke models. NeuroAiD may be able to improve cerebral blood flow and functional recovery after stroke in patients. 11 The main outcome of this study was executive function as measured by the verbal fluency test. Secondary outcomes include cognitive assessments such as ADAS-Cog, MoCA, MMSE, and Cognitive Battery; daily activities as measured by the Alzhei-Mer’s Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale for mild cognitive impairment; behavior as measured by the Neuropsychiatric Inventory; and depression as measured by the Geriatric Depression Scale and Beck Depression Scale. 11 The NEURITES study has the potential to set new standards for the systematic evaluation of traditional Asian medicines for integration into standard medical practice and establish new therapeutic approaches to improve cognition after stroke. 11 Factorial map of the documents with the highest contributes In Figure 4 , the document with the highest contributor is the document entitled The Effect of NeuroAid (MLC901) on Cholestasis-Induced Spatial Memory Impairment with Respect to the Expression of BAX, BCL-2, BAD, PGC-1α, and TFAM Genes in the Hippocampus of Male Wistar Rats by Molaei P, Vaseghi S, Entezari M, Hashemi M, and Nasehi M, published in Neurochem Res, volume 46, pages 2154-2166, on May 24, 2021. 12 Figure 4. Factorial map of the documents with the highest contributes. Documents by author Based on Figure 5 the most authors with 30 documents are Venketasubramanian, N., with the titles of several articles, namely: T Association between Baseline NIHSS Limb Motor Score and Functional Recovery after Stroke: Analysis Based on a Multicountry Dataset, 13 Ischemic Stroke and Savings in Time to Achieve Functional Recovery: Experience from NeuroAiD, 14 Alzheimer’s Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial, 15 NEURoaid II (MLC901) in cognitively Impaired not demenTEd patientS (NEURITES): A pilot double blind, placebo-controlled randomized trial, 16 and NeuroAid II (MLC901) in Haemorrhagic Stroke. 17 Figure 5. Documents by author. The next most author with 20 documents is Chen, C.L.H., with the titles of several articles, namely: Association between Baseline NIHSS Limb Motor Score and Functional Recovery after Stroke: Analysis Based on a Multicountry Dataset, 13 Ischemic Stroke and Savings in Time to Achieve Functional Recovery: Experience from NeuroAiD, 14 Alzheimer’s Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial, 15 NEURoaid II (MLC901) in cognitively Impaired not demenTEd patientS (NEURITES): A pilot double blind, placebo-controlled randomized trial, 16 and article title Frequency and clinical impact of serious adverse events on post-stroke recovery with NeuroAiD (MLC601) versus Placebo: The CHInese medicine neuroaid efficacy on stroke recovery study. 18 Documents by country or territory Based on Figure 6 , Singapore is the country with the largest number of document producers 37 documents. Followed by France with 17 documents, Iran with 16 documents, Malaysia with 13 documents, and the Philippines with 12 documents. Figure 6. Documents by country or territory. Documents by subject area Figure 7. Documents by subject area. Table 1. Documents by subject area. No Title Field of Medicine 1. Facilitation of neurological recovery in a complete spinal cord injury with NeuroAiD: case report 2. Protocol for Safety and Efficacy of MLC901 (NeuroAiD II) in Patients With Moderate Traumatic Brain Injury: A Randomized Double-Blind Placebo- Controlled Trial (ANDROMEDA) 3. Brain computed tomography perfusion analysis in HIV-seropositive adults with and without neurocognitive impairment in Nigeria: outcomes and challenges of a pilot study 4. MLC901 in hypoxic-ischemic brain injury patients: A double-blind, randomized placebo-controlled pilot study 5. Association between Baseline NIHSS Limb Motor Score and Functional Recovery after Stroke: Analysis Based on a Multicountry Dataset 6. Ischemic Stroke and Savings in Time to Achieve Functional Recovery: Experience from NeuroAiD 7. A Long-term Study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer's Disease; An Extension 8- year Follow-up Study 8. INCOG 2.0 Guidelines for Cognitive Rehabilitation Following Traumatic Brain Injury, Part II: Attention and Information Processing Speed 9. Spinal cord injury–assessing tolerability and use of combined rehabilitation and NeuroAiD (SATURN) study–primary results of an exploratory study 10. Clathrin-nanoparticles deliver BDNF to hippocampus and enhance neurogenesis, synaptogenesis and cognition in HIV/neuroAIDS mouse model 11. Randomised, double-blind, placebocontrolled study investigating Safety and efficAcy of MLC901 in posttraUmatic bRAin Injury: The SAMURAI study protocol 12. Alzheimer's Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial 13. NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report 14. NEURoaid II (MLC901) in cognitively Impaired not demenTEd patientS (NEURITES): A pilot double blind, placebo-controlled randomized trial 15. Systematic Review and Meta-Analysis of the Efficacy of MLC901 (NeuroAiD II) for Acute Ischemic Brain Injury in Animal Models 16. NeuroAid II (MLC901) in Haemorrhagic Stroke 17. Role of MLC901 in increasing neurogenesis in rats with traumatic brain injury 18. Frequency and clinical impact of serious adverse events on post-stroke recovery with NeuroAiD (MLC601) versus Placebo: The CHInese medicine neuroaid efficacy on stroke recovery study 19. Effect of cholestasis and NeuroAid treatment on the expression of Bax, Bcl-2, Pgc-1α and Tfam genes involved in apoptosis and mitochondrial biogenesis in the striatum of male rats 20. The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, doubleblind, placebo-controlled trial 21. Effect of Combined Treatment with MLC601 (NeuroAiD) and Rehabilitation on Post-Stroke Recovery: The CHIMES and CHIMESE Studies 22. MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial 23. New directions in treatments targeting stroke recovery 24. Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4- Year Follow-Up Study 25. Therapeutic effect of Chinese herbal medicines for post stroke recovery 26. MLC601 in vascular dementia: An efficacy and safety pilot study 27. Neuroaid for improving recovery after ischemic stroke 28. Intracyctic papillary carcinoma of the breast: Report of a rare case and literature review 29. Durability of the beneficial effect of MLC601 (NeuroAiD™) on functional recovery among stroke patients from the Philippines in the CHIMES and CHIMES-E studies 30. Neuroaid for improving recovery after ischaemic stroke 31. Efficacy and safety of MLC601 in the treatment of mild cognitive impairment: A pilot, randomized, double-blind, placebo-controlled study 32. Prognostic factors and pattern of long-term recovery with MLC601 (NeuroAiD™) in the Chinese medicine NeuroAiD efficacy on stroke recovery - Extension study 33. Sex and the treatment effect in the Chinese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) trial 34. MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice 35. Efficacy of MLC601 on functional recovery after stroke: A systematic review and meta-analysis of randomized controlled trials 36. Comparison between the original and shortened versions of the national institutes of health stroke scale in ischemic stroke patients of intermediate severity 37. The value of patient selection in demonstrating treatment effect in stroke recovery trials: Lessons from the CHIMES study of MLC601 (NeuroAiD) 38. CHInese medicine NeuroAiD efficacy on stroke recovery - Extension study (CHIMES-E): A multicenter study of long-term efficacy 39. Therapeutic Efficacy of Neuro AiD™ (MLC 601), a Traditional Chinese Medicine, in Experimental Traumatic Brain Injury 40. The NeuroAiD Safe Treatment (NeST) Registry: A protocol 41. Prognostic factors and treatment effect in the CHIMES study 42. Developing traditional Chinese medicine in the era of evidence-based medicine: Current evidences and challenges 43. A Randomized trial to assess the long-term safety of NeuroAiD among Caucasian patients with acute ischemic stroke 44. Effects of MLC601 on early vascular events in patients after stroke: The CHIMES study 45. Chinese medicine neuroaid efficacy on stroke recovery: A double-blind, placebo-controlled, randomized study 46. Drugs from natural substances: Why study them in cerebral infarction Bousser, M.-G. Cerebrovascular Diseases 2 View at Publisher Related 47. NeuroAiD (MLC601) and amyloid precursor protein processing 48. Chinese medicine NeuroAiD efficacy stroke recovery - Extension study (CHIMES-E study): An observational multicenter study to investigate the longer-term efficacy of NeuroAiD in stroke recovery 49. NeuroAiD: Properties for neuroprotection and neurorepair 50. Efficacy and safety of MLC601 (NeuroAiD®), a traditional chinese medicine, in poststroke recovery: A systematic review 51. The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES) for the NEURITE investigators 52. Cognitive enhancers (Nootropics). Part 3: Drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs 53. Alternative therapies for stroke treatment in Asia 54. The effect of NeuroAiD™ (MLC601) on cerebral blood flow velocity in subjects' post brain infarct in the middle cerebral artery territory 55. Safety and efficacy of MLC601 in Iranian patients after stroke: A double-blind, placebo-controlled clinical trial 56. Use of Traditional Chinese Medication for post-stroke recovery 57. Safety profile of MLC601 (Neuroaid®) in acute ischemic stroke patients: A Singaporean substudy of the chinese medicine neuroaid efficacy on stroke recovery study 58. A double-blind, placebo-controlled, randomized phase II pilot study to investigate the potential efficacy of the traditional Chinese medicine neuroaid (MLC 601) in enhancing recovery after stroke (TIERS) 59. Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery 60. Neuroaid in stroke recovery 61. Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients Field of Neuroscience 1. Facilitation of neurological recovery in a complete spinal cord injury with NeuroAiD: case report 2. Association between Baseline NIHSS Limb Motor Score and Functional Recovery after Stroke: Analysis Based on a Multicountry Dataset 3. NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report 4. The Effect of NeuroAid (MLC901) on Cholestasis-Induced Spatial Memory Impairment with Respect to the Expression of BAX, BCL-2, BAD, PGC-1α and TFAM Genes in the Hippocampus of Male Wistar Rats 5. A possible neuroprotective property of ethanol and/or NeuroAiD on the modulation of cognitive function 6. Safety and use of MLC601/MLC901 (NeuroAiD™) in primary intracerebral hemorrhage: A cohort study from the NeuroAiD safe treatment registry 7. Frequency and clinical impact of serious adverse events on post-stroke recovery with NeuroAiD (MLC601) versus Placebo: The CHInese medicine neuroaid efficacy on stroke recovery study 8. Effect of cholestasis and NeuroAid treatment on the expression of Bax, Bcl-2, Pgc-1α and Tfam genes involved in apoptosis and mitochondrial biogenesis in the striatum of male rats 9. The potential of mlc901 (Neuroaid ii™), a traditional chinese medicine 10. Effect of Combined Treatment with MLC601 (NeuroAiD) and Rehabilitation on Post-Stroke Recovery: The CHIMES and CHIMESE Studies 11. MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial 12. MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial 13. MLC601 in vascular dementia: An efficacy and safety pilot study 14. Durability of the beneficial effect of MLC601 (NeuroAiD™) on functional recovery among stroke patients from the Philippines in the CHIMES and CHIMES-E studies 15. Efficacy and safety of MLC601 in the treatment of mild cognitive impairment: A pilot, randomized, double-blind, placebo-controlled study 16. Prognostic factors and pattern of long-term recovery with MLC601 (NeuroAiD™) in the Chinese medicine NeuroAiD efficacy on stroke recovery - Extension study 17. The effects of MLC901 on tau phosphorylation 18. Sex and the treatment effect in the Chinese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) trial 19. MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice 20. Efficacy of MLC601 on functional recovery after stroke: A systematic review and meta-analysis of randomized controlled trials 21. Positive effects of the traditional Chinese medicine MLC901 in cognitive tasks 22. CHInese medicine NeuroAiD efficacy on stroke recovery - Extension study (CHIMES-E): A multicenter study of long-term efficacy 23. Therapeutic Efficacy of Neuro AiD™ (MLC 601), a Traditional Chinese Medicine, in Experimental Traumatic Brain Injury 24. Baseline characteristics and treatment response of patients from the Philippines in the CHIMES study 25. MLC901, a Traditional Chinese Medicine induces neuroprotective and neuroregenerative benefits after traumatic brain injury in rats 26. CHIMES-I: Sub-group analyzes of the effects of NeuroAiD according to baseline brain imaging characteristics among patients randomized in the CHIMES study 27. Drugs from natural substances: Why study them in cerebral infarction 28. NeuroAiD (MLC601) and amyloid precursor protein processing 29. Chinese medicine NeuroAiD efficacy stroke recovery - Extension study (CHIMES-E study): An observational multicenter study to investigate the longer-term efficacy of NeuroAiD in stroke recovery 30. NeuroAiD: Properties for neuroprotection and neurorepair 31. Efficacy and safety of MLC601 (NeuroAiD®), a traditional chinese medicine, in poststroke recovery: A systematic review 32. The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES) for the NEURITE investigators 33. Cognitive enhancers (Nootropics). Part 3: Drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs 34. Burden of stroke in the Philippines 35. Activation of ATP-sensitive potassium channels as an element of the neuroprotective effects of the Traditional Chinese Medicine MLC901 against oxygen glucose deprivation 36. Alternative therapies for stroke treatment in Asia 37. MLC901, a Traditional Chinese Medicine protects the brain against global ischemia 38. NeuroAid (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia 39. Safety profile of MLC601 (Neuroaid®) in acute ischemic stroke patients: A Singaporean substudy of the chinese medicine neuroaid efficacy on stroke recovery study 40. Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo 41. A double-blind, placebo-controlled, randomized phase II pilot study to investigate the potential efficacy of the traditional Chinese medicine neuroaid (MLC 601) in enhancing recovery after stroke (TIERS) 42. A double-blind, placebo-controlled, randomized, multicenter study to investigate CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES Study) 43. Neuroaid in stroke recovery 44. Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients Field of Biochemistry, Genetics and Molecular Biology 1. A Long-term Study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer's Disease; An Extension 8- year Follow-up Study 2. Antiepileptic Effect of Neuroaid on Strychnine-Induced Convulsions in Mice 3. Clathrin-nanoparticles deliver BDNF to hippocampus and enhance neurogenesis, synaptogenesis and cognition in HIV/neuroAIDS mouse model 4. The Effect of NeuroAid (MLC901) on Cholestasis-Induced Spatial Memory Impairment with Respect to the Expression of BAX, BCL-2, BAD, PGC-1α and TFAM Genes in the Hippocampus of Male Wistar Rats 5. Effects of morphine and NeuroAid on the expression levels of GluN2A and GluN3A in the hippocampus and striatum of rats 6. The neuroprotective effect of NeuroAid on morphine-induced amnesia with respect to the expression of TFAM, PGC-1α, ΔfosB and CART genes in the hippocampus of male Wistar rats 7. Effect of cholestasis and NeuroAid treatment on the expression of Bax, Bcl-2, Pgc-1α and Tfam genes involved in apoptosis and mitochondrial biogenesis in the striatum of male rats 8. Intracyctic papillary carcinoma of the breast: Report of a rare case and literature review 9. A positive correlation exists between neurotrauma and TGF-β1-containing microglia in rats 10. A pharmacogenomic profile of human neural progenitors undergoing differentiation in the presence of the traditional Chinese medicine NeuroAiD Documents by affiliation Based on Figure 8 , in first place, the producer of the most documents is affiliated with the National University of Singapore with 30 documents, next in second place is affiliated with Raffkes Hospital, Singapore with 17 documents and next is the National Neuroscience Institute of Singapore with 13 documents. Figure 8. Documents by affiliation. Network visualization Based on Figure 9 , it can be seen that the areas studied are still not related to other areas that are divided into edges. That field is: stroke rehabilitation, time to treatment, time factor, procedures, severity of illness index, recovery, in vitro study, mice inbred c57bl, animal cell, mice, disease models animal, pathology, disease model, rats, apoptosis, rats wistar, wistar rat, gene expression, traumatic brain injury, safflower, cognitive defect, nuclear magnecti resonance imaging, neuroaid ii, executive function, nootropic agent, polygalacea, pilot study, drug tolerability, abdominal discomfort, safety, side effect, antihypertensive agent, traditional chinese medicine, brain injuries, hippocampus, cohort analysis, systematic review, brain infarction, brain, and human cell. Figure 9. Network visualization. Overlay visualization of scopus, database using vosviewer Based on Figure 10 , in the overlay visualization, it appears that the keywords that are being researched a lot approaching 2019 are the parts colored yellow, namely: mic901, animal, pscychology, hippocampus, pilot study, cognition, wistar rat, disability, and neuroaid ii. Figure 10. Overlay visualization of scopus, database using Vosviewer. Density visualization Based on Figure 11 , in the visual circulation density, it appears that the part that is already saturated with research is yellow, while the part that is not yet saturated is slightly yellow and dominantly green, namely keywords: stroke rehabilitation, time to treatment, time factor, time factors, procedures, recovery, drug effects, mice inbredc57bl, in vitro study, animal cell, mouse, mice, pathology, cell proliferation, rats, apoptosis, rat, rats wistar, hippocampus, wistar rat, gene expression, neurogenesis, safflower, cognitive defect, nuclear magnetic resonance ima, patient compliance, neuroaid ii, executive function, nootropic agent, pilot study, polygalaceae, naursea, safety, drug tolerability, abdominal discomfort, vomiting, side effect, antihypertensive agent, traditional chinese medicine, stroke recovery, severity of illness index, and cohort analysis. Figure 11. Density visualization. Thematic map Based on Figure 12 , in the niche section there are the keywords cognition, neurogenesis then the keywords effect, treatment, rats then the keywords registry, safe. Figure 12. Thematic map. Thematic evolution Based on Figure 13 , there was an evolution of changes in themes in research in 2008-2017 with the keywords mlc, neuroaid, cognitive, patients, and positive. The theme then changed in 2018-2024 to neuroaid, mlc, recovery, pilot and brain. Figure 13. Thematic evolution. Topic dendogram Based on Figure 14 , there are 2 large clusters based on keywords. There are 2 clusters of blue and red. Figure 14. Dendogram. Table 2. Various research documents on the use of neuroaid. Title Document Reference No. Hemorrhagic stroke 2 1 , 4 Expression of bax Bcl-2 pgc-1alpha Tfam gene 3 12 , 19 , 20 Spinal cord injury 2 9 , 21 Vascular dementia 2 10 , 22 Parkinson 1 23 Traumatic brain injury 8 3 , 24 – 30 Cognitive impairment 5 31 – 35 Hypoxic ischemic brain injury 1 36 Nootropics 1 37 Epilepsy 1 38 Expression GluN2A 1 39 Cardioprotective 1 40 Alzheimer's disease 1 41 Tau phosphorilation 1 42 Amyloid precursor protein processing 2 43 , 44 Ischemic stroke 12 2 , 45 – 55 Neuroprotective 19 56 – 74 Review article 16 5 , 7 , 8 , 75 – 87 Qualitative analysis Word cloud Based on Figure 15 , word cloud shows that the dominance in the document is neuroaid, mlc, stroke, recovery, and study. Figure 15. World cloud. Discussion The niche theme in this study represents a more specific and perhaps less explored area of research in the current literature. For example, keywords such as “cognition” and “neurogenesis” may indicate that there is ongoing research into how neuroaid may affect cognitive function and the growth of new nerve cells. Meanwhile, keywords like “treatment,” “rats,” and “registry safe” may indicate that there is ongoing research into Neuroaid’s use in treatment, testing in mice, and its safety. The motor theme includes keywords such as “brain,” “injury,” and “cognitive,” which may indicate that there is a lot of research that has been done on how Neuroaid can aid in recovery from brain injury and improvement of cognitive function. Other keywords such as “MLC,” “study,” “efficacy,” “Chinese,” “medicine,” “traditional,” “neuroaid,” “stroke,” and “recovery” indicate that there is extensive research on the efficacy of Neuroaid as a Traditional Chinese medicine in stroke recovery. Themes that emerged or decreased were “MLC,” “study,” and “efficacy.” This suggests that research focus may be shifting in this direction or may indicate that research in this area may be declining. For example, if there is a decline in research on the efficacy of Neuroaid, this may indicate that researchers may be switching to another drug or therapy. However, it is important to note that the results from this study may change if different keywords are used. This means that the interpretation of this study should be done with caution, considering that the results may be different if different keywords are used. For example, if the keyword “rehabilitation” is used instead of “recovery,” the results may be very different. Additionally, this bibliometric study is new and uses document data from www.scopus.com . Therefore, the results may not reflect the entire literature available outside of this data source. For example, if there is research published in a journal that is not indexed in Scopus, it will not be included in this study. Nonetheless, this study provides valuable insight into current research trends and potential future research directions in the field of Neuroaid. Neuroids, which were originally used to treat ischemic stroke, have now been used to treat hemorrhagic stroke, intelligent spinal injury, vascular dementia, Parkinson’s, traumatic brain injury, cognitive impairment, hypoxic ischemic brain injury, epilepsy, cardioprotective, and Alzheimer’s. With this bibliometric study, it is hoped that it can increase clinical insight so that neuroids can be included in recommendations and various expert consensuses in fields other than stroke. Conclusion The study focuses on specific research areas and may have limited research on the topic. Key terms include “cognition” and “neurogenesis,” which indicate that neuroaid can influence cognitive function and new behaviors. Key terms include “treatment,” “rats,” and “registry safe,” which indicate that Neuroaid can help in stroke prevention and cognitive function enhancement. Key terms include “MLC,” “study,” and “efficacy,” which indicate that the focus of the study may be limited or irrelevant. However, the study’s findings may differ if different research bodies are used. Interpretation should be done with caution, considering the differences between the two groups. The study also uses bibliometric data from Scopus.com , which may not cover all available literature. Despite this, the study provides valuable insights into the research direction and potential areas of research in neuroscience. Neuroids are used for stroke prevention, hemorrhagic stroke, spinal cord injuries, vascular dementia, Parkinson’s, traumativ brain injury, cognitive impairment, hypoxic ischemic brain injury, epilepsi, cardioprotective, and Alzheimer’s. The bibliometric study can help create a consensus on neuroids for stroke treatment. Author contribution AYS conducts research, gathers data, performs statistical analysis, and produces discussions and conclusions, RV, TDS and DAYS editing. Data availability statement Underlying data Figshare: Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study, https://doi.org/10.6084/m9.figshare.25943860.v1 . 88 Extended data Figshare: PRISMA-ScR checklist: Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study: https://doi.org/10.6084/m9.figshare.25943869.v1 . 89 Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0 ). Software availability VOSviewer software is an open-access tool that can be used as a cost-effective method for any scientometric analysis. 90 References 1. Kumar R, Abu Bakar A, Thanabalan J, et al. : Safety and Use of MLC601/MLC901 (NeuroAiDTM) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry. Brain Sci. 2020; 10 (8). PubMed Abstract | Publisher Full Text | Free Full Text 2. Zhang C, Tao W, Zhang J, et al. : Neuroaid for improving recovery after ischemic stroke. Cochrane Database Syst. Rev. 2017 Aug 26; 2017 (8): CD009757. eCollection 2017 Aug. Publisher Full Text 3. Pilipenko P, Ivanova AA, Kotsiubinskaya YV, et al. : Randomised, double-blind, placebo-controlled study investigating Safety and efficAcy of MLC901 in post-traUmatic bRAin Injury: the SAMURAI study protocol. BMJ Open. 2022; 12 (4): e059167. PubMed Abstract | Publisher Full Text | Free Full Text 4. Tan C-Hoon N, Choy D, Venketasubramanian N: NeuroAid II (MLC901) in Haemorrhagic Stroke. Case Rep. Neurol. 2020; 12 (Suppl. 1): 212–217. Publisher Full Text 5. Ranuh I, Sari GM, Utomo B, et al. : Systematic Review and Meta-Analysis of the Efficacy of MLC901 (NeuroAiD II (TM)) for Acute Ischemic Brain Injury in Animal Models. J. Evid.-Based Integr. Med. 2021; 26 : 2515690X2110392. Publisher Full Text 6. Kumar R, Abu Bakar A, Thanabalan J, et al. : Safety and Use of MLC601/MLC901 (NeuroAiD (TM)) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry. Brain Sci. 2020; 10 (8). PubMed Abstract | Publisher Full Text | Free Full Text 7. Siow CHC: Neuroaid in Stroke Recovery. Eur. Neurol. 2008; 60 (5): 264–266. Publisher Full Text 8. Gan R, Lambert C, Lianting J, et al. : Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients. Cerebrovasc. Dis (Basel, Switzerland). 2008; 25 (5): 450–456. PubMed Abstract | Publisher Full Text 9. Zainudin MF, Abu Hassan SA, Khin NY: Facilitation of neurological recovery in a complete spinal cord injury with NeuroAiD: case report. Spinal Cord Ser. Cases. 2024; 10 (1): 16. PubMed Abstract | Publisher Full Text | Free Full Text 10. Chen CL, Ikram K, Anqi Q, et al. : The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES). Cerebrovasc. Dis (Basel, Switzerland). 2013; 35 Suppl 1 : 23–29. PubMed Abstract | Publisher Full Text 11. Chen C, Ikram K, Qiu A, et al. : The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES) for the NEURITE investigators. Cerebrovasc. Dis. 2013; 35 : 23–29. PubMed Abstract | Publisher Full Text 12. Molaei P, Vaseghi S, Entezari M, et al. : The Effect of NeuroAid (MLC901) on Cholestasis-Induced Spatial Memory Impairment with Respect to the Expression of BAX, BCL-2, BAD, PGC-1α and TFAM Genes in the Hippocampus of Male Wistar Rats. Neurochem. Res. 2021; 46 (8): 2154–2166. PubMed Abstract | Publisher Full Text 13. Chen CLH, Pokharkar Y, Venketasubramanian N: Association between Baseline NIHSS Limb Motor Score and Functional Recovery after Stroke: Analysis Based on a Multicountry Dataset. Cerebrovasc. Dis (Basel, Switzerland). 2023; 52 (2): 160–165. PubMed Abstract | Publisher Full Text 14. Venketasubramanian N, Pokharkar Y, Chai JH, et al. : Ischemic Stroke and Savings in Time to Achieve Functional Recovery: Experience from NeuroAiD. J. Cardiovasc. Dev. Dis. 2023; 10 (3). PubMed Abstract | Publisher Full Text | Free Full Text 15. Chen CLH, Lu Q, Moorakonda RB, et al. : Alzheimer’s Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial. J. Am. Med. Dir. Assoc. 2022; 23 (3): 379–86.e3. PubMed Abstract | Publisher Full Text 16. Chen CLH, Nguyen TH, Marasigan S, et al. : NEURoaid II (MLC901) in cognitively Impaired not demenTEd patientS (NEURITES): A pilot double blind, placebo-controlled randomized trial. Alzheimer’s & dementia (New York, N Y). 2021; 7 (1): e12161. PubMed Abstract | Publisher Full Text | Free Full Text 17. Tan CN, Choy D, Venketasubramanian N: NeuroAid II (MLC901) in Haemorrhagic Stroke. Case Rep. Neurol. 2020; 12 (Suppl 1): 212–217. PubMed Abstract | Publisher Full Text | Free Full Text 18. Venketasubramanian N, Moorakonda RB, Lu Q, et al. : Frequency and Clinical Impact of Serious Adverse Events on Post-Stroke Recovery with NeuroAiD (MLC601) versus Placebo: The CHInese Medicine Neuroaid Efficacy on Stroke Recovery Study. Cerebrovasc. Dis (Basel, Switzerland). 2020; 49 (2): 192–199. PubMed Abstract | Publisher Full Text 19. Nasehi M, Torabinejad S, Hashemi M, et al. : Effect of cholestasis and NeuroAid treatment on the expression of Bax, Bcl-2, Pgc-1α and Tfam genes involved in apoptosis and mitochondrial biogenesis in the striatum of male rats. Metab. Brain Dis. 2020; 35 (1): 183–192. PubMed Abstract | Publisher Full Text 20. Nasehi M, Mohammadi A, Ebrahimi-Ghiri M, et al. : MLC901 during sleep deprivation rescues fear memory disruption in rats. Naunyn Schmiedeberg’s Arch. Pharmacol. 2019; 392 (7): 813–821. PubMed Abstract | Publisher Full Text 21. Kumar R, Htwe O, Baharudin A, et al. : Spinal cord injury - assessing tolerability and use of combined rehabilitation and NeuroAiD (SATURN) study - primary results of an exploratory study. J. Spinal Cord Med. 2023; 46 (4): 682–686. PubMed Abstract | Publisher Full Text | Free Full Text 22. Pakdaman H, Amini Harandi A, Gharagozli K, et al. : MLC601 in vascular dementia: an efficacy and safety pilot study. Neuropsychiatr. Dis. Treat. 2017; 13 : 2551–2557. PubMed Abstract | Publisher Full Text | Free Full Text 23. Kumari E, Shukla MK, Pandey OJ, et al. : NeuroAid: Emotion-Based EEG Analysis for Parkinson’s Disease Identification. IEEE Sensors Letters.IEEE Sens. Lett. 2023; 7 : 1–4. Publisher Full Text 24. Ponsford J, Velikonja D, Janzen S, et al. : INCOG 2.0 Guidelines for Cognitive Rehabilitation Following Traumatic Brain Injury, Part II: Attention and Information Processing Speed. J. Head Trauma Rehabil. 2023; 38 (1): 38–51. PubMed Abstract | Publisher Full Text 25. Theadom A, Barker-Collo S, Jones KM, et al. : MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial. Eur. J. Neurol. 2018; 25 (8): 1055–e82. PubMed Abstract | Publisher Full Text | Free Full Text 26. Quintard H, Lorivel T, Gandin C, et al. : MLC901, a Traditional Chinese Medicine induces neuroprotective and neuroregenerative benefits after traumatic brain injury in rats. Neuroscience. 2014; 277 : 72–86. PubMed Abstract | Publisher Full Text 27. Chio CC, Lin MT, Chang CP, et al. : A positive correlation exists between neurotrauma and TGF-β1-containing microglia in rats. Eur. J. Clin. Investig. 2016; 46 (12): 1063–1069. PubMed Abstract | Publisher Full Text 28. Chua AE, Yacapin VJ, Manalo GL 3rd, et al. : Protocol for Safety and Efficacy of MLC901 (NeuroAiD II) in Patients With Moderate Traumatic Brain Injury: A Randomized Double-Blind Placebo-Controlled Trial (ANDROMEDA). Neurosurgery. 2023; 93 (4): 939–951. PubMed Abstract | Publisher Full Text 29. Rosyidi RM, Priyanto B, Islam AA, et al. : Role of MLC901 in increasing neurogenesis in rats with traumatic brain injury. Ann. Med. Surg. 2012; 2020 (60): 36–40. 30. Tsai MC, Chang CP, Peng SW, et al. : Therapeutic efficacy of Neuro AiD™ (MLC 601), a traditional Chinese medicine, in experimental traumatic brain injury. J. Neuroimmune Pharmacol. 2015; 10 (1): 45–54. PubMed Abstract | Publisher Full Text 31. Ogbole G, Efidi R, Odo J, et al. : Brain computed tomography perfusion analysis in HIV-seropositive adults with and without neurocognitive impairment in Nigeria: outcomes and challenges of a pilot study. Pan Afr. Med. J. 2023; 46 : 15. 32. Pakdaman H, Amini Harandi A, Abbasi M, et al. : Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study. Dement. Geriatr. Cogn. Dis. Extra. 2017; 7 (1): 136–142. PubMed Abstract | Publisher Full Text | Free Full Text 33. Pakdaman H, Amini Harandi A, Gharagozli K, et al. : A Long-term Study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer’s Disease; An Extension 8-year Follow-up Study. Curr. Aging Sci. 2023; 16 (3): 234–239. PubMed Abstract | Publisher Full Text 34. Malboosi N, Nasehi M, Hashemi M, et al. : The neuroprotective effect of NeuroAid on morphine-induced amnesia with respect to the expression of TFAM, PGC-1α, ΔfosB and CART genes in the hippocampus of male Wistar rats. Gene. 2020; 742 : 144601. PubMed Abstract | Publisher Full Text 35. Nasehi M, Zadeh-Tehrani SN, Khakpai F, et al. : A possible neuroprotective property of ethanol and/or NeuroAiD on the modulation of cognitive function. Neurotoxicol. Teratol. 2020; 82 : 106927. PubMed Abstract | Publisher Full Text 36. Pakdaman H, Gharagozli K, Karamiani F, et al. : MLC901 in hypoxic-ischemic brain injury patients: A double-blind, randomized placebo-controlled pilot study. Medicine. 2023; 102 (23): e33914. PubMed Abstract | Publisher Full Text | Free Full Text 37. Froestl W, Pfeifer A, Muhs A: Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs. J. Alzheimers Dis. 2013; 34 (1): 1–114. Publisher Full Text 38. Salim Mahmood A, Ammoo AM, Ali MHM, et al. : Antiepileptic Effect of Neuroaid ® on Strychnine-Induced Convulsions in Mice. Pharmaceuticals (Basel, Switzerland). 2022; 15 (12). Publisher Full Text 39. Heshmatzad K, Nasehi M, Vaseghi S: Effects of morphine and NeuroAid on the expression levels of GluN2A and GluN3A in the hippocampus and striatum of rats. Iran. J. Basic Med. Sci. 2021; 24 (4): 469–475. PubMed Abstract | Publisher Full Text 40. Vincent A, Covinhes A, Barrère C, et al. : Acute and long-term cardioprotective effects of the Traditional Chinese Medicine MLC901 against myocardial ischemia-reperfusion injury in mice. Sci. Rep. 2017; 7 (1): 14701. PubMed Abstract | Publisher Full Text | Free Full Text 41. Pakdaman H, Gharagozli K, Abbasi M, et al. : Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study. Dement. Geriatr. Cogn. Dis. Extra. 2018; 8 (1): 174–179. PubMed Abstract | Publisher Full Text | Free Full Text 42. Lee WT, Hsian CCL, Lim Y-A: The effects of MLC901 on tau phosphorylation. NeuroReport. 2017; 28 (16): 1043–1048. PubMed Abstract | Publisher Full Text 43. Chen CLH, Sharma PR, Tan BY, et al. : The Alzheimer’s disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer’s disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial. Alzheimers Dement (New York, N Y). 2019; 5 : 38–45. PubMed Abstract | Publisher Full Text 44. Lim YA, Murray LA, Lai MK, et al. : NeuroAiD ® (MLC601) and amyloid precursor protein processing. Cerebrovasc. Dis (Basel, Switzerland). 2013; 35 Suppl 1 : 30–37. PubMed Abstract | Publisher Full Text 45. Chen CL, Young SH, Gan HH, et al. : Chinese medicine neuroaid efficacy on stroke recovery: a double-blind, placebo-controlled, randomized study. Stroke. 2013; 44 (8): 2093–2100. PubMed Abstract | Publisher Full Text 46. Venketasubramanian N, Young S, Tay SS, et al. : Chinese medicine NeuroAiD efficacy stroke recovery-extension study (CHIMES-E study): an observational multicenter study to investigate the longer-term efficacy of NeuroAiD in stroke recovery. Cerebrovasc. Dis (Basel, Switzerland). 2013; 35 Suppl 1 : 18–22. PubMed Abstract | Publisher Full Text 47. Lee CF, Venketasubramanian N, Wong KS, et al. : Comparison Between the Original and Shortened Versions of the National Institutes of Health Stroke Scale in Ischemic Stroke Patients of Intermediate Severity. Stroke. 2016; 47 (1): 236–239. PubMed Abstract | Publisher Full Text 48. Chen C, Venketasubramanian N, Gan RN, et al. : Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery. Stroke. 2009; 40 (3): 859–863. PubMed Abstract | Publisher Full Text 49. Kong KH, Wee SK, Ng CY, et al. : A double-blind, placebo-controlled, randomized phase II pilot study to investigate the potential efficacy of the traditional chinese medicine Neuroaid (MLC 601) in enhancing recovery after stroke (TIERS). Cerebrovasc. Dis (Basel, Switzerland). 2009; 28 (5): 514–521. PubMed Abstract | Publisher Full Text 50. Abdul Rashid AM, Md Noh MSF, Yusof Khan AHK, et al. : NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report. Egypt. J. Neurol. Psychiat. Neurosurg. 2021; 57 (1): 151. Publisher Full Text 51. Bavarsad Shahripour R, Hemati A, Hosseinzadeh MA: A randomized trial to assess the long-term safety of NeuroAiD among Caucasian patients with acute ischemic stroke. Chin. J. Integr. Med. 2014; 20 (11): 812–817. PubMed Abstract | Publisher Full Text 52. Harandi AA, Abolfazli R, Hatemian A, et al. : Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial. Stroke Res. Treat. 2011; 2011 : 1–5. Publisher Full Text 53. Young SH, Zhao Y, Koh A, et al. : Safety profile of MLC601 (Neuroaid) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine neuroaid efficacy on stroke recovery study. Cerebrovasc. Dis (Basel, Switzerland). 2010; 30 (1): 1–6. PubMed Abstract | Publisher Full Text 54. Fabiaña NL, Chen CL, Venketasubramanian N, et al. : Sex and the treatment effect in the Chinese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) trial. J. Clin. Neurosci. 2016; 33 : 269–270. PubMed Abstract | Publisher Full Text 55. Widmann C, Gandin C, Petit-Paitel A, et al. : The Traditional Chinese Medicine MLC901 inhibits inflammation processes after focal cerebral ischemia. Sci. Rep. 2018; 8 (1): 18062. PubMed Abstract | Publisher Full Text | Free Full Text 56. Moha Ou Maati H, Borsotto M, Chatelain F, et al. : Activation of ATP-sensitive potassium channels as an element of the neuroprotective effects of the Traditional Chinese Medicine MLC901 against oxygen glucose deprivation. Neuropharmacology. 2012; 63 (4): 692–700. PubMed Abstract | Publisher Full Text 57. Navarro JC, Gan HH, Lao AY, et al. : Baseline characteristics and treatment response of patients from the Philippines in the CHIMES study. International journal of stroke: official journal of the International Stroke. Society. 2014; 9 : 102–105. Publisher Full Text 58. Navarro JC, Chen CL, Lagamayo PD, et al. : CHIMES-I: sub-group analyzes of the effects of NeuroAiD according to baseline brain imaging characteristics among patients randomized in the CHIMES study. Int. J. Stroke. 2013; 8 (6): 491–494. PubMed Abstract | Publisher Full Text 59. Venketasubramanian N, Young SH, Tay SS, et al. : CHInese Medicine NeuroAiD Efficacy on Stroke Recovery - Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy. Cerebrovasc. Dis (Basel, Switzerland). 2015; 39 (5-6): 309–318. PubMed Abstract | Publisher Full Text 60. Venketasubramanian N, Chen CL, Gan RN, et al. : A double-blind, placebo-controlled, randomized, multicenter study to investigate CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES Study). Int. J. Stroke. 2009; 4 (1): 54–60. PubMed Abstract | Publisher Full Text 61. Suwanwela NC, Chen CLH, Lee CF, et al. : Effect of Combined Treatment with MLC601 (NeuroAiDTM) and Rehabilitation on Post-Stroke Recovery: The CHIMES and CHIMES-E Studies. Cerebrovasc. Dis (Basel, Switzerland). 2018; 46 (1-2): 82–88. PubMed Abstract | Publisher Full Text | Free Full Text 62. Chen CL, Venketasubramanian N, Lee CF, et al. : Effects of MLC601 on early vascular events in patients after stroke: the CHIMES study. Stroke. 2013; 44 (12): 3580–3583. PubMed Abstract | Publisher Full Text 63. Siddiqui FJ, Venketasubramanian N, Chan ES, et al. : Efficacy and safety of MLC601 (NeuroAiD ® ), a traditional Chinese medicine, in poststroke recovery: a systematic review. Cerebrovasc. Dis (Basel, Switzerland). 2013; 35 Suppl 1 : 8–17. PubMed Abstract | Publisher Full Text 64. González-Fraile E, Martín-Carrasco M, Ballesteros J: Efficacy of MLC601 on functional recovery after stroke: A systematic review and meta-analysis of randomized controlled trials. Brain Inj. 2016; 30 (3): 267–270. PubMed Abstract | Publisher Full Text 65. Gandin C, Widmann C, Lazdunski M, et al. : MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice. Cerebrovasc. Dis (Basel, Switzerland). 2016; 42 (1-2): 139–154. PubMed Abstract | Publisher Full Text 66. Quintard H, Borsotto M, Veyssiere J, et al. : MLC901, a traditional Chinese medicine protects the brain against global ischemia. Neuropharmacology. 2011; 61 (4): 622–631. PubMed Abstract | Publisher Full Text 67. Venketasubramanian N, Kumar R, Soertidewi L, et al. : The NeuroAiD Safe Treatment (NeST) Registry: a protocol. BMJ Open. 2015; 5 (11): e009866. PubMed Abstract | Publisher Full Text | Free Full Text 68. Heurteaux C, Widmann C, Moha ou Maati H, et al. : NeuroAiD: properties for neuroprotection and neurorepair. Cerebrovascular diseases (Basel, Switzerland). 2013; 35 Suppl 1 : 1–7. PubMed Abstract | Publisher Full Text 69. Heurteaux C, Gandin C, Borsotto M, et al. : Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology. 2010; 58 (7): 987–1001. PubMed Abstract | Publisher Full Text 70. Lorivel T, Gandin C, Veyssière J, et al. : Positive effects of the traditional Chinese medicine MLC901 in cognitive tasks. J. Neurosci. Res. 2015; 93 (11): 1648–1663. PubMed Abstract | Publisher Full Text | Free Full Text 71. Venketasubramanian N, Lee CF, Young SH, et al. : Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery - Extension Study. Cerebrovasc. Dis (Basel, Switzerland). 2017; 43 (1-2): 36–42. PubMed Abstract | Publisher Full Text | Free Full Text 72. Chankrachang S, Navarro JC, de Silva DA , et al. : Prognostic factors and treatment effect in the CHIMES study. J. Stroke Cerebrovasc. Dis. 2015; 24 (4): 823–827. PubMed Abstract | Publisher Full Text 73. Sidddiqi SA, Kamal AK: Use of traditional Chinese medication for post-stroke recovery. J. Pak. Med. Assoc. 2011; 61 (9): 933–934. PubMed Abstract 74. Venketasubramanian N, Lee CF, Wong KS, et al. : The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD). J. Evid. Based Med. 2015; 8 (3): 149–153. PubMed Abstract | Publisher Full Text | Free Full Text 75. Pandian JD, Liu M, Misbach J, et al. : Alternative Therapies for Stroke Treatment in Asia. Int. J. Stroke. 2011; 6 (6): 541–543. Publisher Full Text 76. Loo KW, Gan SH: Burden of stroke in the Philippines. Int. J. Stroke. 2013; 8 (2): 131–134. Publisher Full Text 77. Vitaliano GD, Kim JK, Kaufman MJ, et al. : Clathrin-nanoparticles deliver BDNF to hippocampus and enhance neurogenesis, synaptogenesis and cognition in HIV/neuroAIDS mouse model. Commun. Biol. 2022; 5 (1): 236. PubMed Abstract | Publisher Full Text | Free Full Text 78. Fung FY, Linn YC: Developing traditional chinese medicine in the era of evidence-based medicine: current evidences and challenges. Evid. Based Complement. Alternat. Med. 2015; 2015 : 425037. 79. Bousser M-G: Drugs from Natural Substances: Why Study Them in Cerebral Infarction. Cerebrovasc. Dis. 2013; 35 (Suppl. 1): IV–VI. PubMed Abstract | Publisher Full Text 80. Navarro JC, Chen CLH, Lee CF, et al. : Durability of the beneficial effect of MLC601 (NeuroAiD™) on functional recovery among stroke patients from the Philippines in the CHIMES and CHIMES-E studies. Int. J. Stroke. 2016; 12 (3): 285–291. PubMed Abstract | Publisher Full Text 81. Lee HP, Liu YC, Lin MF: Effects of Different Genres of Music on the Psycho-Physiological Responses of Undergraduates. Hu li za zhi J. Nurs. 2016; 63 (6): 77–88. PubMed Abstract | Publisher Full Text 82. Mortazavi N, Novin K, Bidari Zerehpoosh F, et al. : Intracyctic Papillary Carcinoma of the Breast: Report of a Rare Case and Literature Review.2017; 10 (7): e7259. 83. Ghandehari K, Mood Z, Ebrahimzadeh S, et al. : NeuroAid (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia. Neural Regen. Res. 2011; 6 : 418–422. 84. Lin DJ, Finklestein SP, Cramer SC: New Directions in Treatments Targeting Stroke Recovery. Stroke. 2018; 49 (12): 3107–3114. PubMed Abstract | Publisher Full Text | Free Full Text 85. Shoshan-Barmatz V, Mizrachi D, Keinan N: Oligomerization of the mitochondrial protein VDAC1: from structure to function and cancer therapy. Prog. Mol. Biol. Transl. Sci. 2013; 117 : 303–334. Publisher Full Text 86. Huang S, Mingxia L, Xiaowei Pan XP, et al. : The potential of MLC901 (NeuroAiD II™), a traditional Chinese medicine. Neurosci. Res. Notes. 2019; 2 : 18–24. Publisher Full Text 87. Han S-Y, Hong Z-Y, Xie Y-H, et al. : Therapeutic effect of Chinese herbal medicines for post stroke recovery: A traditional and network meta-analysis. Medicine. 2017; 96 (49): e8830. PubMed Abstract | Publisher Full Text | Free Full Text 88. Saleh AY: Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study. figshare. Figure. 2024. Publisher Full Text 89. Saleh AY: PRISMA_2020_checklist_AYS. figshare. Dataset. 2024. Publisher Full Text 90. van Eck NJ , Waltman L: Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017; 111 (2): 1053–1070. Publisher Full Text Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 16 Jul 2024 ADD YOUR COMMENT Comment Author details Author details 1 Neurology Department Faculty of Medicine, UPN Veteran Jakarta, Jakarta, Special Capital Region of Jakarta, 12450, Indonesia 2 Family Medicine and Primary Care, Universitas Pelita Harapan, Tangerang, Banten, 15811, Indonesia 3 Department of Public Health Sciences, Faculty of Medicine, UPN Veteran Jakarta, Jakarta, Special Capital Region of Jakarta, 12450, Indonesia ARMAN YURISALDI SALEH Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation Riezky Valentina Roles: Writing – Review & Editing Tirta Darmawan Susanto Roles: Validation, Writing – Review & Editing Dwi Arwandi Yogi Saputra Roles: Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. Article Versions (2) version 2 Revised Published: 18 Sep 2025, 13:799 https://doi.org/10.12688/f1000research.152581.2 version 1 Published: 16 Jul 2024, 13:799 https://doi.org/10.12688/f1000research.152581.1 Copyright © 2025 SALEH AY et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article SALEH AY, Valentina R, Susanto TD and Saputra DAY. Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] . F1000Research 2025, 13 :799 ( https://doi.org/10.12688/f1000research.152581.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 2 VERSION 2 PUBLISHED 18 Sep 2025 Revised Views 0 Cite How to cite this report: Li Hsian Chen C. Reviewer Report For: Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] . F1000Research 2025, 13 :799 ( https://doi.org/10.5256/f1000research.188303.r415318 ) The direct URL for this report is: https://f1000research.com/articles/13-799/v2#referee-response-415318 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 27 Sep 2025 Christopher Li Hsian Chen , National University of Singapore, Singapore, Singapore Approved VIEWS 0 https://doi.org/10.5256/f1000research.188303.r415318 I have reviewed the article and ... Continue reading READ ALL I have reviewed the article and have no additional comments. I approve it. Competing Interests: No competing interests were disclosed. Reviewer Expertise: Translational medicine, Memory and Aging, Stroke, Clinical Trials, Neuroscience I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Li Hsian Chen C. Reviewer Report For: Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] . F1000Research 2025, 13 :799 ( https://doi.org/10.5256/f1000research.188303.r415318 ) The direct URL for this report is: https://f1000research.com/articles/13-799/v2#referee-response-415318 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 05 Nov 2025 ARMAN YURISALDI SALEH , Neurology Department Faculty of Medicine, UPN Veteran Jakarta, Jakarta, 12450, Indonesia 05 Nov 2025 Author Response Thank you to the reviewers for their kindness in providing feedback and suggestions. Competing Interests: No Competing Interest Thank you to the reviewers for their kindness in providing feedback and suggestions. Thank you to the reviewers for their kindness in providing feedback and suggestions. Competing Interests: No Competing Interest Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 05 Nov 2025 ARMAN YURISALDI SALEH , Neurology Department Faculty of Medicine, UPN Veteran Jakarta, Jakarta, 12450, Indonesia 05 Nov 2025 Author Response Thank you to the reviewers for their kindness in providing feedback and suggestions. Competing Interests: No Competing Interest Thank you to the reviewers for their kindness in providing feedback and suggestions. Thank you to the reviewers for their kindness in providing feedback and suggestions. Competing Interests: No Competing Interest Close Report a concern COMMENT ON THIS REPORT Version 1 VERSION 1 PUBLISHED 16 Jul 2024 Views 0 Cite How to cite this report: Li Hsian Chen C. Reviewer Report For: Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] . F1000Research 2025, 13 :799 ( https://doi.org/10.5256/f1000research.167360.r402766 ) The direct URL for this report is: https://f1000research.com/articles/13-799/v1#referee-response-402766 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 16 Sep 2025 Christopher Li Hsian Chen , National University of Singapore, Singapore, Singapore Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.167360.r402766 The article “Beyond stroke therapy, NeuroAiD (a Chinese herbal) has an effect on cognition and neurogenesis: a bibliometric study” presents the first bibliometric analysis of the research landscape on NeuroAiD (MLC601/MLC901), a traditional Chinese herbal formulation originally developed for stroke ... Continue reading READ ALL The article “Beyond stroke therapy, NeuroAiD (a Chinese herbal) has an effect on cognition and neurogenesis: a bibliometric study” presents the first bibliometric analysis of the research landscape on NeuroAiD (MLC601/MLC901), a traditional Chinese herbal formulation originally developed for stroke recovery. NeuroAiD has been the subject of increasing investigation in preclinical and clinical studies, not only in post-stroke rehabilitation but also in relation to cognition, neurogenesis, and potential applications in conditions such as Alzheimer’s disease, traumatic brain injury, and other neurodegenerative disorders. Key Findings and Conclusions The results confirm a steady growth of NeuroAiD-related publications, with Singapore and associated research groups being especially prominent contributors. Stroke therapy remains the dominant research theme, but clusters around “cognition” and “neurogenesis” have emerged, reflecting diversification of research interests. The most cited works include clinical trials (such as CHIMES) and systematic reviews, while preclinical studies also contribute to thematic diversity. The authors conclude that research is expanding beyond its initial focus on stroke recovery to broader neurological and cognitive contexts. They further suggest that bibliometric findings may support the development of consensus recommendations and highlight promising directions for future clinical investigation. Novelty and Interest The article is novel in being the first bibliometric synthesis of NeuroAiD research, filling an identifiable gap in the literature. By systematically mapping research output, it provides useful insights for clinicians, researchers, and policy-makers interested in complementary and integrative approaches to neurorehabilitation. The visualizations help reveal collaboration networks and research trajectories, which may guide future scientific planning. Limitations as a Scientific Publication Despite its originality, the study has some methodological limitations. First, the reliance on a single database (Scopus) and a single keyword (“NeuroAiD”) risks missing relevant publications indexed under synonyms (e.g., MLC601, MLC901, Danqi Piantan Jiaonang). Second, reproducibility is limited by the lack of detail on search strategy parameters, inclusion/exclusion criteria, and bibliometric software settings. Third, while the figures are generally clear, their interpretation occasionally overreaches by inferring therapeutic implications (e.g., stroke prevention, cognitive enhancement) from keyword clustering, which bibliometric mapping alone cannot establish. Finally, the conclusions would benefit from more cautious framing, emphasizing research trends rather than clinical efficacy. Overall Assessment The study represents a timely and original contribution, offering a structured overview of how NeuroAiD research has developed and where it may be heading. Its main strength lies in novelty and descriptive clarity, but its scientific impact would be stronger if methodological transparency were enhanced and interpretive claims were more carefully aligned with the descriptive nature of bibliometric evidence. 1. Are the rationale for, and objectives of, the Systematic Review clearly stated? NeuroAiD is introduced as a traditional herbal formulation with applications in stroke recovery, cognition, and neurogenesis. The rationale is clear: while many clinical and preclinical studies exist, no bibliometric mapping has been performed. Strengths: - The gap is well identified: absence of bibliometric studies despite a large literature base. - Objectives to analyze research trends, contributors, and thematic evolution are explicit. Limitations: - The introduction mixes pharmacological background with bibliometric rationale, which dilutes focus. - Objectives could be sharper, ideally set out as 1–2 bullet points rather than embedded in long paragraphs. - Stronger linkage to how bibliometric insights can inform pharmacology and clinical research strategies or policy directions would improve the rationale. 2. Are sufficient details of the methods and analysis provided to allow replication by others? The general workflow is presented (Scopus search → CSV/RIS export → analysis with Biblioshiny and VOSviewer), but key details are insufficient for full replication. Strengths: - Database (Scopus), search field (TITLE-ABS-KEY), and timeframe (May 2024) are reported. - Analytical tools are clearly identified and commonly used in bibliometric research. Limitations: - Only one keyword ('NeuroAiD') was used, excluding synonyms such as 'MLC601,' 'MLC901,' or 'Danqi Piantan Jiaonang.' On the other hand, a few publications listed in the References seem to be irrelevant to NeuroAiD (see for example Ref. 23, 31, 81, 82, 85) - No inclusion/exclusion criteria or language filters were reported. - Data were extracted by one reviewer, with no mention of error-checking or inter-rater reliability. - No reporting of threshold parameters in VOSviewer/Biblioshiny, making replication of maps impossible. - The dataset (92 documents) is not openly shared, which limits validation. 3. Is the statistical analysis and its interpretation appropriate? The analysis is descriptive (publication counts, keyword clustering, co-authorship networks) and appropriate for bibliometrics. However, interpretation extends beyond what the methods can support. Figures and visual displays are integral to the study, and their clarity and interpretation also require assessment. Strengths: - Appropriate use of standard bibliometric techniques and visualization tools such as co-authorship networks, thematic mapping, and keyword clustering. - Figures (documents per year, factorial maps, thematic maps, word clouds) illustrate results effectively and make complex patterns more accessible. - Most figures are clearly titled and correctly captioned, adding descriptive value. - Identification of most cited papers, productive countries, and thematic clusters is valid and well aligned with bibliometric outputs. Limitations: - Lack of detail on statistical thresholds (e.g., co-occurrence strength, minimum citation counts) reduces reproducibility. - Some figures (network visualizations, density maps) are visually complex and not fully self-explanatory for readers unfamiliar with bibliometric software. - Legends sometimes assume prior knowledge of visualization conventions and could be made clearer. 4. Are the conclusions drawn adequately supported by the results presented in the review? The conclusions summarize observed research trends but sometimes make claims that exceed the descriptive scope of bibliometrics. Strengths: - Accurately reflect publication growth, geographic distribution, and thematic emphasis on cognition and neurogenesis. - Some limitations (Scopus-only data) are acknowledged. Limitations: - Overgeneralization to multiple conditions (Parkinson’s, epilepsy) is not justified. - Discussion underemphasizes citation clustering and network bias. - A more cautious conclusion would frame the study as mapping research directions, not only evaluating therapeutic effectiveness. 5. If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? This article is not designed or presented as a Living Systematic Review (LSR). The methodology corresponds to a one-time bibliometric analysis conducted on Scopus data in May 2024. Since it is not framed as a Living Systematic Review, criteria regarding search update schedules, predefined intervals, and ongoing maintenance do not apply. To avoid confusion, the authors could clarify explicitly in the methods or title that the work is a cross-sectional bibliometric study, not a living review. Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? No Is the statistical analysis and its interpretation appropriate? Partly Are the conclusions drawn adequately supported by the results presented in the review? Partly If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? (‘Living Systematic Review’ or a variation of this term should be included in the title.) Not applicable Competing Interests: No competing interests were disclosed. Reviewer Expertise: Translational medicine, Memory and Aging, Stroke, Clinical Trials, Neuroscience I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Li Hsian Chen C. Reviewer Report For: Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] . F1000Research 2025, 13 :799 ( https://doi.org/10.5256/f1000research.167360.r402766 ) The direct URL for this report is: https://f1000research.com/articles/13-799/v1#referee-response-402766 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 22 Sep 2025 ARMAN YURISALDI SALEH , Neurology Department Faculty of Medicine, UPN Veteran Jakarta, Jakarta, 12450, Indonesia 22 Sep 2025 Author Response Thank you for the detailed and constructive feedback during the peer review process. 1. Are the rationale for, and objectives of, the Systematic Review clearly stated? NeuroAiD is introduced ... Continue reading Thank you for the detailed and constructive feedback during the peer review process. 1. Are the rationale for, and objectives of, the Systematic Review clearly stated? NeuroAiD is introduced as a traditional herbal formulation with applications in stroke recovery, cognition, and neurogenesis. The rationale is clear: while many clinical and preclinical studies exist, no bibliometric mapping has been performed. Strengths: - The gap is well identified: absence of bibliometric studies despite a large literature base. - Objectives to analyze research trends, contributors, and thematic evolution are explicit. Limitations: - The introduction mixes pharmacological background with bibliometric rationale, which dilutes focus. - Objectives could be sharper, ideally set out as 1–2 bullet points rather than embedded in long paragraphs. - Stronger linkage to how bibliometric insights can inform pharmacology and clinical research strategies or policy directions would improve the rationale. Introduction NeuroAiD (MLC601/MLC901) is a traditional Chinese medicine formulation that has gained global attention for its role in post-stroke recovery. MLC601 contains nine herbal and five animal-derived components, while MLC901 is a simplified, animal-free version with comparable neuroprotective properties. Both have demonstrated efficacy in enhancing neurological recovery, promoting neurogenesis, and supporting cognitive function in conditions such as Alzheimer’s disease and traumatic brain injury. Despite the growing body of clinical and preclinical research, no bibliometric study has systematically mapped the scientific landscape surrounding NeuroAiD. Bibliometric analysis offers a powerful tool to: Identify research trends, thematic evolution, and collaboration networks. Inform future pharmacological research, clinical strategies, and policy development through evidence-based insights. Objectives This study aims to: Analyze publication trends, geographic distribution, and institutional contributions in NeuroAiD research from 2008 to 2024. Identify the most prolific authors, journals, and subject areas associated with NeuroAiD. Map thematic evolution and keyword clusters using bibliometric tools (Biblioshiny and VOSviewer). 2. Are sufficient details of the methods and analysis provided to allow replication by others? The general workflow is presented (Scopus search → CSV/RIS export → analysis with Biblioshiny and VOSviewer), but key details are insufficient for full replication. Strengths: - Database (Scopus), search field (TITLE-ABS-KEY), and timeframe (May 2024) are reported. - Analytical tools are clearly identified and commonly used in bibliometric research. Limitations: - Only one keyword ('NeuroAiD') was used, excluding synonyms such as 'MLC601,' 'MLC901,' or 'Danqi Piantan Jiaonang.' On the other hand, a few publications listed in the References seem to be irrelevant to NeuroAiD (see for example Ref. 23, 31, 81, 82, 85) - No inclusion/exclusion criteria or language filters were reported. - Data were extracted by one reviewer, with no mention of error-checking or inter-rater reliability. - No reporting of threshold parameters in VOSviewer/Biblioshiny, making replication of maps impossible. - The dataset (92 documents) is not openly shared, which limits validation. Thank you for the constructive feedback. We acknowledge that while the general workflow was outlined, several methodological details require clarification to ensure replicability. The search was conducted in Scopus using the TITLE-ABS-KEY field with the keyword “NeuroAiD” in May 2024. We recognize that excluding synonyms such as “MLC601,” “MLC901,” and “Danqi Piantan Jiaonang” may have limited the dataset and will address this in future updates. No language filters or inclusion/exclusion criteria were applied; this will be explicitly stated in the revised Methods section. Data extraction was performed by a single reviewer; we agree that inter-rater reliability and error-checking procedures should be described and will be incorporated. Threshold parameters used in VOSviewer and Biblioshiny (e.g., minimum co-occurrence, citation cut-offs) were not reported and will be added to support reproducibility. The dataset of 92 documents has now been made openly available via Figshare [https://doi.org/10.6084/m9.figshare.25943860.v1] to facilitate validation and transparency. 3. Is the statistical analysis and its interpretation appropriate? The analysis is descriptive (publication counts, keyword clustering, co-authorship networks) and appropriate for bibliometrics. However, interpretation extends beyond what the methods can support. Figures and visual displays are integral to the study, and their clarity and interpretation also require assessment. Strengths: - Appropriate use of standard bibliometric techniques and visualization tools such as co-authorship networks, thematic mapping, and keyword clustering. - Figures (documents per year, factorial maps, thematic maps, word clouds) illustrate results effectively and make complex patterns more accessible. - Most figures are clearly titled and correctly captioned, adding descriptive value. - Identification of most cited papers, productive countries, and thematic clusters is valid and well aligned with bibliometric outputs. Limitations: - Lack of detail on statistical thresholds (e.g., co-occurrence strength, minimum citation counts) reduces reproducibility. - Some figures (network visualizations, density maps) are visually complex and not fully self-explanatory for readers unfamiliar with bibliometric software. - Legends sometimes assume prior knowledge of visualization conventions and could be made clearer. Thank you for your constructive feedback. We agree that the analysis used is descriptive and in line with the bibliometric approach. Visualizations such as thematic maps, word clouds, and collaboration networks have been used to clarify publication patterns and research themes. However, we acknowledge that the interpretation of some sections needs to be adjusted to ensure they do not exceed the capabilities of the methods used. In the future, we will add details regarding statistical thresholds (e.g., strength of co-occurrence and minimum citation count) and clarify the legends and explanations of the visualizations to make them more understandable for the general reader. 4. Are the conclusions drawn adequately supported by the results presented in the review? The conclusions summarize observed research trends but sometimes make claims that exceed the descriptive scope of bibliometrics. Strengths: - Accurately reflect publication growth, geographic distribution, and thematic emphasis on cognition and neurogenesis. - Some limitations (Scopus-only data) are acknowledged. Limitations: - Overgeneralization to multiple conditions (Parkinson’s, epilepsy) is not justified. - Discussion underemphasizes citation clustering and network bias. - A more cautious conclusion would frame the study as mapping research directions, not only evaluating therapeutic effectiveness. Thank you for the thoughtful feedback. We acknowledge that our conclusions may have extended beyond the descriptive scope of bibliometric analysis. In response, we have revised the conclusion to emphasize that this study primarily maps research directions and thematic trends in NeuroAiD-related literature, rather than evaluating therapeutic efficacy. While we noted emerging interest in conditions such as Parkinson’s and epilepsy, we now clarify that these references reflect exploratory research trajectories rather than established clinical applications. We also recognize the limitations of Scopus-only data and have added a note on potential citation clustering and network bias. These adjustments aim to align our interpretations more closely with the methodological boundaries of bibliometric research. 5. If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? This article is not designed or presented as a Living Systematic Review (LSR). The methodology corresponds to a one-time bibliometric analysis conducted on Scopus data in May 2024. Since it is not framed as a Living Systematic Review, criteria regarding search update schedules, predefined intervals, and ongoing maintenance do not apply. To avoid confusion, the authors could clarify explicitly in the methods or title that the work is a cross-sectional bibliometric study, not a living review. Thank you for the comment. We clarify that this study is designed as a systematic review with a bibliometric approach. Although it does not follow the “living” review format, it systematically identifies, analyzes, and synthesizes published literature on NeuroAiD using predefined inclusion criteria and a transparent search strategy. The data extraction and analysis were conducted in accordance with established bibliometric review standards. We have updated the Methods section to explicitly state that this is a systematic, cross-sectional bibliometric review rather than a Living Systematic Review. Best Regard Arman Thank you for the detailed and constructive feedback during the peer review process. 1. Are the rationale for, and objectives of, the Systematic Review clearly stated? NeuroAiD is introduced as a traditional herbal formulation with applications in stroke recovery, cognition, and neurogenesis. The rationale is clear: while many clinical and preclinical studies exist, no bibliometric mapping has been performed. Strengths: - The gap is well identified: absence of bibliometric studies despite a large literature base. - Objectives to analyze research trends, contributors, and thematic evolution are explicit. Limitations: - The introduction mixes pharmacological background with bibliometric rationale, which dilutes focus. - Objectives could be sharper, ideally set out as 1–2 bullet points rather than embedded in long paragraphs. - Stronger linkage to how bibliometric insights can inform pharmacology and clinical research strategies or policy directions would improve the rationale. Introduction NeuroAiD (MLC601/MLC901) is a traditional Chinese medicine formulation that has gained global attention for its role in post-stroke recovery. MLC601 contains nine herbal and five animal-derived components, while MLC901 is a simplified, animal-free version with comparable neuroprotective properties. Both have demonstrated efficacy in enhancing neurological recovery, promoting neurogenesis, and supporting cognitive function in conditions such as Alzheimer’s disease and traumatic brain injury. Despite the growing body of clinical and preclinical research, no bibliometric study has systematically mapped the scientific landscape surrounding NeuroAiD. Bibliometric analysis offers a powerful tool to: Identify research trends, thematic evolution, and collaboration networks. Inform future pharmacological research, clinical strategies, and policy development through evidence-based insights. Objectives This study aims to: Analyze publication trends, geographic distribution, and institutional contributions in NeuroAiD research from 2008 to 2024. Identify the most prolific authors, journals, and subject areas associated with NeuroAiD. Map thematic evolution and keyword clusters using bibliometric tools (Biblioshiny and VOSviewer). 2. Are sufficient details of the methods and analysis provided to allow replication by others? The general workflow is presented (Scopus search → CSV/RIS export → analysis with Biblioshiny and VOSviewer), but key details are insufficient for full replication. Strengths: - Database (Scopus), search field (TITLE-ABS-KEY), and timeframe (May 2024) are reported. - Analytical tools are clearly identified and commonly used in bibliometric research. Limitations: - Only one keyword ('NeuroAiD') was used, excluding synonyms such as 'MLC601,' 'MLC901,' or 'Danqi Piantan Jiaonang.' On the other hand, a few publications listed in the References seem to be irrelevant to NeuroAiD (see for example Ref. 23, 31, 81, 82, 85) - No inclusion/exclusion criteria or language filters were reported. - Data were extracted by one reviewer, with no mention of error-checking or inter-rater reliability. - No reporting of threshold parameters in VOSviewer/Biblioshiny, making replication of maps impossible. - The dataset (92 documents) is not openly shared, which limits validation. Thank you for the constructive feedback. We acknowledge that while the general workflow was outlined, several methodological details require clarification to ensure replicability. The search was conducted in Scopus using the TITLE-ABS-KEY field with the keyword “NeuroAiD” in May 2024. We recognize that excluding synonyms such as “MLC601,” “MLC901,” and “Danqi Piantan Jiaonang” may have limited the dataset and will address this in future updates. No language filters or inclusion/exclusion criteria were applied; this will be explicitly stated in the revised Methods section. Data extraction was performed by a single reviewer; we agree that inter-rater reliability and error-checking procedures should be described and will be incorporated. Threshold parameters used in VOSviewer and Biblioshiny (e.g., minimum co-occurrence, citation cut-offs) were not reported and will be added to support reproducibility. The dataset of 92 documents has now been made openly available via Figshare [https://doi.org/10.6084/m9.figshare.25943860.v1] to facilitate validation and transparency. 3. Is the statistical analysis and its interpretation appropriate? The analysis is descriptive (publication counts, keyword clustering, co-authorship networks) and appropriate for bibliometrics. However, interpretation extends beyond what the methods can support. Figures and visual displays are integral to the study, and their clarity and interpretation also require assessment. Strengths: - Appropriate use of standard bibliometric techniques and visualization tools such as co-authorship networks, thematic mapping, and keyword clustering. - Figures (documents per year, factorial maps, thematic maps, word clouds) illustrate results effectively and make complex patterns more accessible. - Most figures are clearly titled and correctly captioned, adding descriptive value. - Identification of most cited papers, productive countries, and thematic clusters is valid and well aligned with bibliometric outputs. Limitations: - Lack of detail on statistical thresholds (e.g., co-occurrence strength, minimum citation counts) reduces reproducibility. - Some figures (network visualizations, density maps) are visually complex and not fully self-explanatory for readers unfamiliar with bibliometric software. - Legends sometimes assume prior knowledge of visualization conventions and could be made clearer. Thank you for your constructive feedback. We agree that the analysis used is descriptive and in line with the bibliometric approach. Visualizations such as thematic maps, word clouds, and collaboration networks have been used to clarify publication patterns and research themes. However, we acknowledge that the interpretation of some sections needs to be adjusted to ensure they do not exceed the capabilities of the methods used. In the future, we will add details regarding statistical thresholds (e.g., strength of co-occurrence and minimum citation count) and clarify the legends and explanations of the visualizations to make them more understandable for the general reader. 4. Are the conclusions drawn adequately supported by the results presented in the review? The conclusions summarize observed research trends but sometimes make claims that exceed the descriptive scope of bibliometrics. Strengths: - Accurately reflect publication growth, geographic distribution, and thematic emphasis on cognition and neurogenesis. - Some limitations (Scopus-only data) are acknowledged. Limitations: - Overgeneralization to multiple conditions (Parkinson’s, epilepsy) is not justified. - Discussion underemphasizes citation clustering and network bias. - A more cautious conclusion would frame the study as mapping research directions, not only evaluating therapeutic effectiveness. Thank you for the thoughtful feedback. We acknowledge that our conclusions may have extended beyond the descriptive scope of bibliometric analysis. In response, we have revised the conclusion to emphasize that this study primarily maps research directions and thematic trends in NeuroAiD-related literature, rather than evaluating therapeutic efficacy. While we noted emerging interest in conditions such as Parkinson’s and epilepsy, we now clarify that these references reflect exploratory research trajectories rather than established clinical applications. We also recognize the limitations of Scopus-only data and have added a note on potential citation clustering and network bias. These adjustments aim to align our interpretations more closely with the methodological boundaries of bibliometric research. 5. If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? This article is not designed or presented as a Living Systematic Review (LSR). The methodology corresponds to a one-time bibliometric analysis conducted on Scopus data in May 2024. Since it is not framed as a Living Systematic Review, criteria regarding search update schedules, predefined intervals, and ongoing maintenance do not apply. To avoid confusion, the authors could clarify explicitly in the methods or title that the work is a cross-sectional bibliometric study, not a living review. Thank you for the comment. We clarify that this study is designed as a systematic review with a bibliometric approach. Although it does not follow the “living” review format, it systematically identifies, analyzes, and synthesizes published literature on NeuroAiD using predefined inclusion criteria and a transparent search strategy. The data extraction and analysis were conducted in accordance with established bibliometric review standards. We have updated the Methods section to explicitly state that this is a systematic, cross-sectional bibliometric review rather than a Living Systematic Review. Best Regard Arman Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 22 Sep 2025 ARMAN YURISALDI SALEH , Neurology Department Faculty of Medicine, UPN Veteran Jakarta, Jakarta, 12450, Indonesia 22 Sep 2025 Author Response Thank you for the detailed and constructive feedback during the peer review process. 1. Are the rationale for, and objectives of, the Systematic Review clearly stated? NeuroAiD is introduced ... Continue reading Thank you for the detailed and constructive feedback during the peer review process. 1. Are the rationale for, and objectives of, the Systematic Review clearly stated? NeuroAiD is introduced as a traditional herbal formulation with applications in stroke recovery, cognition, and neurogenesis. The rationale is clear: while many clinical and preclinical studies exist, no bibliometric mapping has been performed. Strengths: - The gap is well identified: absence of bibliometric studies despite a large literature base. - Objectives to analyze research trends, contributors, and thematic evolution are explicit. Limitations: - The introduction mixes pharmacological background with bibliometric rationale, which dilutes focus. - Objectives could be sharper, ideally set out as 1–2 bullet points rather than embedded in long paragraphs. - Stronger linkage to how bibliometric insights can inform pharmacology and clinical research strategies or policy directions would improve the rationale. Introduction NeuroAiD (MLC601/MLC901) is a traditional Chinese medicine formulation that has gained global attention for its role in post-stroke recovery. MLC601 contains nine herbal and five animal-derived components, while MLC901 is a simplified, animal-free version with comparable neuroprotective properties. Both have demonstrated efficacy in enhancing neurological recovery, promoting neurogenesis, and supporting cognitive function in conditions such as Alzheimer’s disease and traumatic brain injury. Despite the growing body of clinical and preclinical research, no bibliometric study has systematically mapped the scientific landscape surrounding NeuroAiD. Bibliometric analysis offers a powerful tool to: Identify research trends, thematic evolution, and collaboration networks. Inform future pharmacological research, clinical strategies, and policy development through evidence-based insights. Objectives This study aims to: Analyze publication trends, geographic distribution, and institutional contributions in NeuroAiD research from 2008 to 2024. Identify the most prolific authors, journals, and subject areas associated with NeuroAiD. Map thematic evolution and keyword clusters using bibliometric tools (Biblioshiny and VOSviewer). 2. Are sufficient details of the methods and analysis provided to allow replication by others? The general workflow is presented (Scopus search → CSV/RIS export → analysis with Biblioshiny and VOSviewer), but key details are insufficient for full replication. Strengths: - Database (Scopus), search field (TITLE-ABS-KEY), and timeframe (May 2024) are reported. - Analytical tools are clearly identified and commonly used in bibliometric research. Limitations: - Only one keyword ('NeuroAiD') was used, excluding synonyms such as 'MLC601,' 'MLC901,' or 'Danqi Piantan Jiaonang.' On the other hand, a few publications listed in the References seem to be irrelevant to NeuroAiD (see for example Ref. 23, 31, 81, 82, 85) - No inclusion/exclusion criteria or language filters were reported. - Data were extracted by one reviewer, with no mention of error-checking or inter-rater reliability. - No reporting of threshold parameters in VOSviewer/Biblioshiny, making replication of maps impossible. - The dataset (92 documents) is not openly shared, which limits validation. Thank you for the constructive feedback. We acknowledge that while the general workflow was outlined, several methodological details require clarification to ensure replicability. The search was conducted in Scopus using the TITLE-ABS-KEY field with the keyword “NeuroAiD” in May 2024. We recognize that excluding synonyms such as “MLC601,” “MLC901,” and “Danqi Piantan Jiaonang” may have limited the dataset and will address this in future updates. No language filters or inclusion/exclusion criteria were applied; this will be explicitly stated in the revised Methods section. Data extraction was performed by a single reviewer; we agree that inter-rater reliability and error-checking procedures should be described and will be incorporated. Threshold parameters used in VOSviewer and Biblioshiny (e.g., minimum co-occurrence, citation cut-offs) were not reported and will be added to support reproducibility. The dataset of 92 documents has now been made openly available via Figshare [https://doi.org/10.6084/m9.figshare.25943860.v1] to facilitate validation and transparency. 3. Is the statistical analysis and its interpretation appropriate? The analysis is descriptive (publication counts, keyword clustering, co-authorship networks) and appropriate for bibliometrics. However, interpretation extends beyond what the methods can support. Figures and visual displays are integral to the study, and their clarity and interpretation also require assessment. Strengths: - Appropriate use of standard bibliometric techniques and visualization tools such as co-authorship networks, thematic mapping, and keyword clustering. - Figures (documents per year, factorial maps, thematic maps, word clouds) illustrate results effectively and make complex patterns more accessible. - Most figures are clearly titled and correctly captioned, adding descriptive value. - Identification of most cited papers, productive countries, and thematic clusters is valid and well aligned with bibliometric outputs. Limitations: - Lack of detail on statistical thresholds (e.g., co-occurrence strength, minimum citation counts) reduces reproducibility. - Some figures (network visualizations, density maps) are visually complex and not fully self-explanatory for readers unfamiliar with bibliometric software. - Legends sometimes assume prior knowledge of visualization conventions and could be made clearer. Thank you for your constructive feedback. We agree that the analysis used is descriptive and in line with the bibliometric approach. Visualizations such as thematic maps, word clouds, and collaboration networks have been used to clarify publication patterns and research themes. However, we acknowledge that the interpretation of some sections needs to be adjusted to ensure they do not exceed the capabilities of the methods used. In the future, we will add details regarding statistical thresholds (e.g., strength of co-occurrence and minimum citation count) and clarify the legends and explanations of the visualizations to make them more understandable for the general reader. 4. Are the conclusions drawn adequately supported by the results presented in the review? The conclusions summarize observed research trends but sometimes make claims that exceed the descriptive scope of bibliometrics. Strengths: - Accurately reflect publication growth, geographic distribution, and thematic emphasis on cognition and neurogenesis. - Some limitations (Scopus-only data) are acknowledged. Limitations: - Overgeneralization to multiple conditions (Parkinson’s, epilepsy) is not justified. - Discussion underemphasizes citation clustering and network bias. - A more cautious conclusion would frame the study as mapping research directions, not only evaluating therapeutic effectiveness. Thank you for the thoughtful feedback. We acknowledge that our conclusions may have extended beyond the descriptive scope of bibliometric analysis. In response, we have revised the conclusion to emphasize that this study primarily maps research directions and thematic trends in NeuroAiD-related literature, rather than evaluating therapeutic efficacy. While we noted emerging interest in conditions such as Parkinson’s and epilepsy, we now clarify that these references reflect exploratory research trajectories rather than established clinical applications. We also recognize the limitations of Scopus-only data and have added a note on potential citation clustering and network bias. These adjustments aim to align our interpretations more closely with the methodological boundaries of bibliometric research. 5. If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? This article is not designed or presented as a Living Systematic Review (LSR). The methodology corresponds to a one-time bibliometric analysis conducted on Scopus data in May 2024. Since it is not framed as a Living Systematic Review, criteria regarding search update schedules, predefined intervals, and ongoing maintenance do not apply. To avoid confusion, the authors could clarify explicitly in the methods or title that the work is a cross-sectional bibliometric study, not a living review. Thank you for the comment. We clarify that this study is designed as a systematic review with a bibliometric approach. Although it does not follow the “living” review format, it systematically identifies, analyzes, and synthesizes published literature on NeuroAiD using predefined inclusion criteria and a transparent search strategy. The data extraction and analysis were conducted in accordance with established bibliometric review standards. We have updated the Methods section to explicitly state that this is a systematic, cross-sectional bibliometric review rather than a Living Systematic Review. Best Regard Arman Thank you for the detailed and constructive feedback during the peer review process. 1. Are the rationale for, and objectives of, the Systematic Review clearly stated? NeuroAiD is introduced as a traditional herbal formulation with applications in stroke recovery, cognition, and neurogenesis. The rationale is clear: while many clinical and preclinical studies exist, no bibliometric mapping has been performed. Strengths: - The gap is well identified: absence of bibliometric studies despite a large literature base. - Objectives to analyze research trends, contributors, and thematic evolution are explicit. Limitations: - The introduction mixes pharmacological background with bibliometric rationale, which dilutes focus. - Objectives could be sharper, ideally set out as 1–2 bullet points rather than embedded in long paragraphs. - Stronger linkage to how bibliometric insights can inform pharmacology and clinical research strategies or policy directions would improve the rationale. Introduction NeuroAiD (MLC601/MLC901) is a traditional Chinese medicine formulation that has gained global attention for its role in post-stroke recovery. MLC601 contains nine herbal and five animal-derived components, while MLC901 is a simplified, animal-free version with comparable neuroprotective properties. Both have demonstrated efficacy in enhancing neurological recovery, promoting neurogenesis, and supporting cognitive function in conditions such as Alzheimer’s disease and traumatic brain injury. Despite the growing body of clinical and preclinical research, no bibliometric study has systematically mapped the scientific landscape surrounding NeuroAiD. Bibliometric analysis offers a powerful tool to: Identify research trends, thematic evolution, and collaboration networks. Inform future pharmacological research, clinical strategies, and policy development through evidence-based insights. Objectives This study aims to: Analyze publication trends, geographic distribution, and institutional contributions in NeuroAiD research from 2008 to 2024. Identify the most prolific authors, journals, and subject areas associated with NeuroAiD. Map thematic evolution and keyword clusters using bibliometric tools (Biblioshiny and VOSviewer). 2. Are sufficient details of the methods and analysis provided to allow replication by others? The general workflow is presented (Scopus search → CSV/RIS export → analysis with Biblioshiny and VOSviewer), but key details are insufficient for full replication. Strengths: - Database (Scopus), search field (TITLE-ABS-KEY), and timeframe (May 2024) are reported. - Analytical tools are clearly identified and commonly used in bibliometric research. Limitations: - Only one keyword ('NeuroAiD') was used, excluding synonyms such as 'MLC601,' 'MLC901,' or 'Danqi Piantan Jiaonang.' On the other hand, a few publications listed in the References seem to be irrelevant to NeuroAiD (see for example Ref. 23, 31, 81, 82, 85) - No inclusion/exclusion criteria or language filters were reported. - Data were extracted by one reviewer, with no mention of error-checking or inter-rater reliability. - No reporting of threshold parameters in VOSviewer/Biblioshiny, making replication of maps impossible. - The dataset (92 documents) is not openly shared, which limits validation. Thank you for the constructive feedback. We acknowledge that while the general workflow was outlined, several methodological details require clarification to ensure replicability. The search was conducted in Scopus using the TITLE-ABS-KEY field with the keyword “NeuroAiD” in May 2024. We recognize that excluding synonyms such as “MLC601,” “MLC901,” and “Danqi Piantan Jiaonang” may have limited the dataset and will address this in future updates. No language filters or inclusion/exclusion criteria were applied; this will be explicitly stated in the revised Methods section. Data extraction was performed by a single reviewer; we agree that inter-rater reliability and error-checking procedures should be described and will be incorporated. Threshold parameters used in VOSviewer and Biblioshiny (e.g., minimum co-occurrence, citation cut-offs) were not reported and will be added to support reproducibility. The dataset of 92 documents has now been made openly available via Figshare [https://doi.org/10.6084/m9.figshare.25943860.v1] to facilitate validation and transparency. 3. Is the statistical analysis and its interpretation appropriate? The analysis is descriptive (publication counts, keyword clustering, co-authorship networks) and appropriate for bibliometrics. However, interpretation extends beyond what the methods can support. Figures and visual displays are integral to the study, and their clarity and interpretation also require assessment. Strengths: - Appropriate use of standard bibliometric techniques and visualization tools such as co-authorship networks, thematic mapping, and keyword clustering. - Figures (documents per year, factorial maps, thematic maps, word clouds) illustrate results effectively and make complex patterns more accessible. - Most figures are clearly titled and correctly captioned, adding descriptive value. - Identification of most cited papers, productive countries, and thematic clusters is valid and well aligned with bibliometric outputs. Limitations: - Lack of detail on statistical thresholds (e.g., co-occurrence strength, minimum citation counts) reduces reproducibility. - Some figures (network visualizations, density maps) are visually complex and not fully self-explanatory for readers unfamiliar with bibliometric software. - Legends sometimes assume prior knowledge of visualization conventions and could be made clearer. Thank you for your constructive feedback. We agree that the analysis used is descriptive and in line with the bibliometric approach. Visualizations such as thematic maps, word clouds, and collaboration networks have been used to clarify publication patterns and research themes. However, we acknowledge that the interpretation of some sections needs to be adjusted to ensure they do not exceed the capabilities of the methods used. In the future, we will add details regarding statistical thresholds (e.g., strength of co-occurrence and minimum citation count) and clarify the legends and explanations of the visualizations to make them more understandable for the general reader. 4. Are the conclusions drawn adequately supported by the results presented in the review? The conclusions summarize observed research trends but sometimes make claims that exceed the descriptive scope of bibliometrics. Strengths: - Accurately reflect publication growth, geographic distribution, and thematic emphasis on cognition and neurogenesis. - Some limitations (Scopus-only data) are acknowledged. Limitations: - Overgeneralization to multiple conditions (Parkinson’s, epilepsy) is not justified. - Discussion underemphasizes citation clustering and network bias. - A more cautious conclusion would frame the study as mapping research directions, not only evaluating therapeutic effectiveness. Thank you for the thoughtful feedback. We acknowledge that our conclusions may have extended beyond the descriptive scope of bibliometric analysis. In response, we have revised the conclusion to emphasize that this study primarily maps research directions and thematic trends in NeuroAiD-related literature, rather than evaluating therapeutic efficacy. While we noted emerging interest in conditions such as Parkinson’s and epilepsy, we now clarify that these references reflect exploratory research trajectories rather than established clinical applications. We also recognize the limitations of Scopus-only data and have added a note on potential citation clustering and network bias. These adjustments aim to align our interpretations more closely with the methodological boundaries of bibliometric research. 5. If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? This article is not designed or presented as a Living Systematic Review (LSR). The methodology corresponds to a one-time bibliometric analysis conducted on Scopus data in May 2024. Since it is not framed as a Living Systematic Review, criteria regarding search update schedules, predefined intervals, and ongoing maintenance do not apply. To avoid confusion, the authors could clarify explicitly in the methods or title that the work is a cross-sectional bibliometric study, not a living review. Thank you for the comment. We clarify that this study is designed as a systematic review with a bibliometric approach. Although it does not follow the “living” review format, it systematically identifies, analyzes, and synthesizes published literature on NeuroAiD using predefined inclusion criteria and a transparent search strategy. The data extraction and analysis were conducted in accordance with established bibliometric review standards. We have updated the Methods section to explicitly state that this is a systematic, cross-sectional bibliometric review rather than a Living Systematic Review. Best Regard Arman Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Leung PC. Reviewer Report For: Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] . F1000Research 2025, 13 :799 ( https://doi.org/10.5256/f1000research.167360.r305119 ) The direct URL for this report is: https://f1000research.com/articles/13-799/v1#referee-response-305119 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 02 Aug 2024 Ping-Chung Leung , The Chinese University of Hong Kong, Hong Kong, Hong Kong Approved VIEWS 0 https://doi.org/10.5256/f1000research.167360.r305119 Stroke is a common debilitating disease with yet no standard treatment to improve the physical outcomes and mental disturbances during the rehabilitation period. Use of Herbal medicine is yet a controversial form of remedy not widely accepted. The use of ... Continue reading READ ALL Stroke is a common debilitating disease with yet no standard treatment to improve the physical outcomes and mental disturbances during the rehabilitation period. Use of Herbal medicine is yet a controversial form of remedy not widely accepted. The use of substances of animal origin is another worrying component. Authors rightly completed a thorough search for the support of using Euro Aid. Apparently, most of the references originate from the CHIMES study. Authors could discuss, via the literature reviews, all the points raised above. Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? Yes Is the statistical analysis and its interpretation appropriate? Yes Are the conclusions drawn adequately supported by the results presented in the review? Yes If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? (‘Living Systematic Review’ or a variation of this term should be included in the title.) Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Research on traditional medicine I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Leung PC. Reviewer Report For: Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] . F1000Research 2025, 13 :799 ( https://doi.org/10.5256/f1000research.167360.r305119 ) The direct URL for this report is: https://f1000research.com/articles/13-799/v1#referee-response-305119 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 06 Aug 2024 ARMAN YURISALDI SALEH , Neurology Department Faculty of Medicine, UPN Veteran Jakarta, Jakarta, 12450, Indonesia 06 Aug 2024 Author Response Thank you to the reviewers for their kindness in providing feedback and suggestions. Competing Interests: No competing interests were disclosed. Thank you to the reviewers for their kindness in providing feedback and suggestions. Thank you to the reviewers for their kindness in providing feedback and suggestions. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 06 Aug 2024 ARMAN YURISALDI SALEH , Neurology Department Faculty of Medicine, UPN Veteran Jakarta, Jakarta, 12450, Indonesia 06 Aug 2024 Author Response Thank you to the reviewers for their kindness in providing feedback and suggestions. Competing Interests: No competing interests were disclosed. Thank you to the reviewers for their kindness in providing feedback and suggestions. Thank you to the reviewers for their kindness in providing feedback and suggestions. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 16 Jul 2024 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 Version 2 (revision) 18 Sep 25 read Version 1 16 Jul 24 read read Ping-Chung Leung , The Chinese University of Hong Kong, Hong Kong, Hong Kong Christopher Li Hsian Chen , National University of Singapore, Singapore, Singapore Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Li Hsian Chen C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 27 Sep 2025 | for Version 2 Christopher Li Hsian Chen , National University of Singapore, Singapore, Singapore 0 Views copyright © 2025 Li Hsian Chen C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions I have reviewed the article and have no additional comments. I approve it. Competing Interests No competing interests were disclosed. Reviewer Expertise Translational medicine, Memory and Aging, Stroke, Clinical Trials, Neuroscience I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 05 Nov 2025 ARMAN YURISALDI SALEH, Neurology Department Faculty of Medicine, UPN Veteran Jakarta, Jakarta, 12450, Indonesia Thank you to the reviewers for their kindness in providing feedback and suggestions. View more View less Competing Interests No Competing Interest reply Respond Report a concern Li Hsian Chen C. Peer Review Report For: Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] . F1000Research 2025, 13 :799 ( https://doi.org/10.5256/f1000research.188303.r415318) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-799/v2#referee-response-415318 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Li Hsian Chen C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 16 Sep 2025 | for Version 1 Christopher Li Hsian Chen , National University of Singapore, Singapore, Singapore 0 Views copyright © 2025 Li Hsian Chen C. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The article “Beyond stroke therapy, NeuroAiD (a Chinese herbal) has an effect on cognition and neurogenesis: a bibliometric study” presents the first bibliometric analysis of the research landscape on NeuroAiD (MLC601/MLC901), a traditional Chinese herbal formulation originally developed for stroke recovery. NeuroAiD has been the subject of increasing investigation in preclinical and clinical studies, not only in post-stroke rehabilitation but also in relation to cognition, neurogenesis, and potential applications in conditions such as Alzheimer’s disease, traumatic brain injury, and other neurodegenerative disorders. Key Findings and Conclusions The results confirm a steady growth of NeuroAiD-related publications, with Singapore and associated research groups being especially prominent contributors. Stroke therapy remains the dominant research theme, but clusters around “cognition” and “neurogenesis” have emerged, reflecting diversification of research interests. The most cited works include clinical trials (such as CHIMES) and systematic reviews, while preclinical studies also contribute to thematic diversity. The authors conclude that research is expanding beyond its initial focus on stroke recovery to broader neurological and cognitive contexts. They further suggest that bibliometric findings may support the development of consensus recommendations and highlight promising directions for future clinical investigation. Novelty and Interest The article is novel in being the first bibliometric synthesis of NeuroAiD research, filling an identifiable gap in the literature. By systematically mapping research output, it provides useful insights for clinicians, researchers, and policy-makers interested in complementary and integrative approaches to neurorehabilitation. The visualizations help reveal collaboration networks and research trajectories, which may guide future scientific planning. Limitations as a Scientific Publication Despite its originality, the study has some methodological limitations. First, the reliance on a single database (Scopus) and a single keyword (“NeuroAiD”) risks missing relevant publications indexed under synonyms (e.g., MLC601, MLC901, Danqi Piantan Jiaonang). Second, reproducibility is limited by the lack of detail on search strategy parameters, inclusion/exclusion criteria, and bibliometric software settings. Third, while the figures are generally clear, their interpretation occasionally overreaches by inferring therapeutic implications (e.g., stroke prevention, cognitive enhancement) from keyword clustering, which bibliometric mapping alone cannot establish. Finally, the conclusions would benefit from more cautious framing, emphasizing research trends rather than clinical efficacy. Overall Assessment The study represents a timely and original contribution, offering a structured overview of how NeuroAiD research has developed and where it may be heading. Its main strength lies in novelty and descriptive clarity, but its scientific impact would be stronger if methodological transparency were enhanced and interpretive claims were more carefully aligned with the descriptive nature of bibliometric evidence. 1. Are the rationale for, and objectives of, the Systematic Review clearly stated? NeuroAiD is introduced as a traditional herbal formulation with applications in stroke recovery, cognition, and neurogenesis. The rationale is clear: while many clinical and preclinical studies exist, no bibliometric mapping has been performed. Strengths: - The gap is well identified: absence of bibliometric studies despite a large literature base. - Objectives to analyze research trends, contributors, and thematic evolution are explicit. Limitations: - The introduction mixes pharmacological background with bibliometric rationale, which dilutes focus. - Objectives could be sharper, ideally set out as 1–2 bullet points rather than embedded in long paragraphs. - Stronger linkage to how bibliometric insights can inform pharmacology and clinical research strategies or policy directions would improve the rationale. 2. Are sufficient details of the methods and analysis provided to allow replication by others? The general workflow is presented (Scopus search → CSV/RIS export → analysis with Biblioshiny and VOSviewer), but key details are insufficient for full replication. Strengths: - Database (Scopus), search field (TITLE-ABS-KEY), and timeframe (May 2024) are reported. - Analytical tools are clearly identified and commonly used in bibliometric research. Limitations: - Only one keyword ('NeuroAiD') was used, excluding synonyms such as 'MLC601,' 'MLC901,' or 'Danqi Piantan Jiaonang.' On the other hand, a few publications listed in the References seem to be irrelevant to NeuroAiD (see for example Ref. 23, 31, 81, 82, 85) - No inclusion/exclusion criteria or language filters were reported. - Data were extracted by one reviewer, with no mention of error-checking or inter-rater reliability. - No reporting of threshold parameters in VOSviewer/Biblioshiny, making replication of maps impossible. - The dataset (92 documents) is not openly shared, which limits validation. 3. Is the statistical analysis and its interpretation appropriate? The analysis is descriptive (publication counts, keyword clustering, co-authorship networks) and appropriate for bibliometrics. However, interpretation extends beyond what the methods can support. Figures and visual displays are integral to the study, and their clarity and interpretation also require assessment. Strengths: - Appropriate use of standard bibliometric techniques and visualization tools such as co-authorship networks, thematic mapping, and keyword clustering. - Figures (documents per year, factorial maps, thematic maps, word clouds) illustrate results effectively and make complex patterns more accessible. - Most figures are clearly titled and correctly captioned, adding descriptive value. - Identification of most cited papers, productive countries, and thematic clusters is valid and well aligned with bibliometric outputs. Limitations: - Lack of detail on statistical thresholds (e.g., co-occurrence strength, minimum citation counts) reduces reproducibility. - Some figures (network visualizations, density maps) are visually complex and not fully self-explanatory for readers unfamiliar with bibliometric software. - Legends sometimes assume prior knowledge of visualization conventions and could be made clearer. 4. Are the conclusions drawn adequately supported by the results presented in the review? The conclusions summarize observed research trends but sometimes make claims that exceed the descriptive scope of bibliometrics. Strengths: - Accurately reflect publication growth, geographic distribution, and thematic emphasis on cognition and neurogenesis. - Some limitations (Scopus-only data) are acknowledged. Limitations: - Overgeneralization to multiple conditions (Parkinson’s, epilepsy) is not justified. - Discussion underemphasizes citation clustering and network bias. - A more cautious conclusion would frame the study as mapping research directions, not only evaluating therapeutic effectiveness. 5. If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? This article is not designed or presented as a Living Systematic Review (LSR). The methodology corresponds to a one-time bibliometric analysis conducted on Scopus data in May 2024. Since it is not framed as a Living Systematic Review, criteria regarding search update schedules, predefined intervals, and ongoing maintenance do not apply. To avoid confusion, the authors could clarify explicitly in the methods or title that the work is a cross-sectional bibliometric study, not a living review. Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? No Is the statistical analysis and its interpretation appropriate? Partly Are the conclusions drawn adequately supported by the results presented in the review? Partly If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? (‘Living Systematic Review’ or a variation of this term should be included in the title.) Not applicable Competing Interests No competing interests were disclosed. Reviewer Expertise Translational medicine, Memory and Aging, Stroke, Clinical Trials, Neuroscience I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 22 Sep 2025 ARMAN YURISALDI SALEH, Neurology Department Faculty of Medicine, UPN Veteran Jakarta, Jakarta, 12450, Indonesia Thank you for the detailed and constructive feedback during the peer review process. 1. Are the rationale for, and objectives of, the Systematic Review clearly stated? NeuroAiD is introduced as a traditional herbal formulation with applications in stroke recovery, cognition, and neurogenesis. The rationale is clear: while many clinical and preclinical studies exist, no bibliometric mapping has been performed. Strengths: - The gap is well identified: absence of bibliometric studies despite a large literature base. - Objectives to analyze research trends, contributors, and thematic evolution are explicit. Limitations: - The introduction mixes pharmacological background with bibliometric rationale, which dilutes focus. - Objectives could be sharper, ideally set out as 1–2 bullet points rather than embedded in long paragraphs. - Stronger linkage to how bibliometric insights can inform pharmacology and clinical research strategies or policy directions would improve the rationale. Introduction NeuroAiD (MLC601/MLC901) is a traditional Chinese medicine formulation that has gained global attention for its role in post-stroke recovery. MLC601 contains nine herbal and five animal-derived components, while MLC901 is a simplified, animal-free version with comparable neuroprotective properties. Both have demonstrated efficacy in enhancing neurological recovery, promoting neurogenesis, and supporting cognitive function in conditions such as Alzheimer’s disease and traumatic brain injury. Despite the growing body of clinical and preclinical research, no bibliometric study has systematically mapped the scientific landscape surrounding NeuroAiD. Bibliometric analysis offers a powerful tool to: Identify research trends, thematic evolution, and collaboration networks. Inform future pharmacological research, clinical strategies, and policy development through evidence-based insights. Objectives This study aims to: Analyze publication trends, geographic distribution, and institutional contributions in NeuroAiD research from 2008 to 2024. Identify the most prolific authors, journals, and subject areas associated with NeuroAiD. Map thematic evolution and keyword clusters using bibliometric tools (Biblioshiny and VOSviewer). 2. Are sufficient details of the methods and analysis provided to allow replication by others? The general workflow is presented (Scopus search → CSV/RIS export → analysis with Biblioshiny and VOSviewer), but key details are insufficient for full replication. Strengths: - Database (Scopus), search field (TITLE-ABS-KEY), and timeframe (May 2024) are reported. - Analytical tools are clearly identified and commonly used in bibliometric research. Limitations: - Only one keyword ('NeuroAiD') was used, excluding synonyms such as 'MLC601,' 'MLC901,' or 'Danqi Piantan Jiaonang.' On the other hand, a few publications listed in the References seem to be irrelevant to NeuroAiD (see for example Ref. 23, 31, 81, 82, 85) - No inclusion/exclusion criteria or language filters were reported. - Data were extracted by one reviewer, with no mention of error-checking or inter-rater reliability. - No reporting of threshold parameters in VOSviewer/Biblioshiny, making replication of maps impossible. - The dataset (92 documents) is not openly shared, which limits validation. Thank you for the constructive feedback. We acknowledge that while the general workflow was outlined, several methodological details require clarification to ensure replicability. The search was conducted in Scopus using the TITLE-ABS-KEY field with the keyword “NeuroAiD” in May 2024. We recognize that excluding synonyms such as “MLC601,” “MLC901,” and “Danqi Piantan Jiaonang” may have limited the dataset and will address this in future updates. No language filters or inclusion/exclusion criteria were applied; this will be explicitly stated in the revised Methods section. Data extraction was performed by a single reviewer; we agree that inter-rater reliability and error-checking procedures should be described and will be incorporated. Threshold parameters used in VOSviewer and Biblioshiny (e.g., minimum co-occurrence, citation cut-offs) were not reported and will be added to support reproducibility. The dataset of 92 documents has now been made openly available via Figshare [https://doi.org/10.6084/m9.figshare.25943860.v1] to facilitate validation and transparency. 3. Is the statistical analysis and its interpretation appropriate? The analysis is descriptive (publication counts, keyword clustering, co-authorship networks) and appropriate for bibliometrics. However, interpretation extends beyond what the methods can support. Figures and visual displays are integral to the study, and their clarity and interpretation also require assessment. Strengths: - Appropriate use of standard bibliometric techniques and visualization tools such as co-authorship networks, thematic mapping, and keyword clustering. - Figures (documents per year, factorial maps, thematic maps, word clouds) illustrate results effectively and make complex patterns more accessible. - Most figures are clearly titled and correctly captioned, adding descriptive value. - Identification of most cited papers, productive countries, and thematic clusters is valid and well aligned with bibliometric outputs. Limitations: - Lack of detail on statistical thresholds (e.g., co-occurrence strength, minimum citation counts) reduces reproducibility. - Some figures (network visualizations, density maps) are visually complex and not fully self-explanatory for readers unfamiliar with bibliometric software. - Legends sometimes assume prior knowledge of visualization conventions and could be made clearer. Thank you for your constructive feedback. We agree that the analysis used is descriptive and in line with the bibliometric approach. Visualizations such as thematic maps, word clouds, and collaboration networks have been used to clarify publication patterns and research themes. However, we acknowledge that the interpretation of some sections needs to be adjusted to ensure they do not exceed the capabilities of the methods used. In the future, we will add details regarding statistical thresholds (e.g., strength of co-occurrence and minimum citation count) and clarify the legends and explanations of the visualizations to make them more understandable for the general reader. 4. Are the conclusions drawn adequately supported by the results presented in the review? The conclusions summarize observed research trends but sometimes make claims that exceed the descriptive scope of bibliometrics. Strengths: - Accurately reflect publication growth, geographic distribution, and thematic emphasis on cognition and neurogenesis. - Some limitations (Scopus-only data) are acknowledged. Limitations: - Overgeneralization to multiple conditions (Parkinson’s, epilepsy) is not justified. - Discussion underemphasizes citation clustering and network bias. - A more cautious conclusion would frame the study as mapping research directions, not only evaluating therapeutic effectiveness. Thank you for the thoughtful feedback. We acknowledge that our conclusions may have extended beyond the descriptive scope of bibliometric analysis. In response, we have revised the conclusion to emphasize that this study primarily maps research directions and thematic trends in NeuroAiD-related literature, rather than evaluating therapeutic efficacy. While we noted emerging interest in conditions such as Parkinson’s and epilepsy, we now clarify that these references reflect exploratory research trajectories rather than established clinical applications. We also recognize the limitations of Scopus-only data and have added a note on potential citation clustering and network bias. These adjustments aim to align our interpretations more closely with the methodological boundaries of bibliometric research. 5. If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? This article is not designed or presented as a Living Systematic Review (LSR). The methodology corresponds to a one-time bibliometric analysis conducted on Scopus data in May 2024. Since it is not framed as a Living Systematic Review, criteria regarding search update schedules, predefined intervals, and ongoing maintenance do not apply. To avoid confusion, the authors could clarify explicitly in the methods or title that the work is a cross-sectional bibliometric study, not a living review. Thank you for the comment. We clarify that this study is designed as a systematic review with a bibliometric approach. Although it does not follow the “living” review format, it systematically identifies, analyzes, and synthesizes published literature on NeuroAiD using predefined inclusion criteria and a transparent search strategy. The data extraction and analysis were conducted in accordance with established bibliometric review standards. We have updated the Methods section to explicitly state that this is a systematic, cross-sectional bibliometric review rather than a Living Systematic Review. Best Regard Arman View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Li Hsian Chen C. Peer Review Report For: Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] . F1000Research 2025, 13 :799 ( https://doi.org/10.5256/f1000research.167360.r402766) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-799/v1#referee-response-402766 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Leung P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 02 Aug 2024 | for Version 1 Ping-Chung Leung , The Chinese University of Hong Kong, Hong Kong, Hong Kong 0 Views copyright © 2024 Leung P. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Stroke is a common debilitating disease with yet no standard treatment to improve the physical outcomes and mental disturbances during the rehabilitation period. Use of Herbal medicine is yet a controversial form of remedy not widely accepted. The use of substances of animal origin is another worrying component. Authors rightly completed a thorough search for the support of using Euro Aid. Apparently, most of the references originate from the CHIMES study. Authors could discuss, via the literature reviews, all the points raised above. Are the rationale for, and objectives of, the Systematic Review clearly stated? Yes Are sufficient details of the methods and analysis provided to allow replication by others? Yes Is the statistical analysis and its interpretation appropriate? Yes Are the conclusions drawn adequately supported by the results presented in the review? Yes If this is a Living Systematic Review, is the ‘living’ method appropriate and is the search schedule clearly defined and justified? (‘Living Systematic Review’ or a variation of this term should be included in the title.) Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Research on traditional medicine I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 06 Aug 2024 ARMAN YURISALDI SALEH, Neurology Department Faculty of Medicine, UPN Veteran Jakarta, Jakarta, 12450, Indonesia Thank you to the reviewers for their kindness in providing feedback and suggestions. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Leung PC. Peer Review Report For: Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] . F1000Research 2025, 13 :799 ( https://doi.org/10.5256/f1000research.167360.r305119) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/13-799/v1#referee-response-305119 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Beyond stroke therapy, neuroaid (a chinese...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/13-799/v2" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/13-799/v2&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/13-799/v2" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('SALEH AY et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/13-799/v2/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/13-799", templates : { twitter : "Beyond stroke therapy, neuroaid (a chinese herbal) has an effect.... SALEH AY et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/13-799/v2" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/152581/188303") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "188303"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "356231": 0, "343938": 0, "326540": 0, "334477": 0, "356237": 0, "326541": 0, "334476": 0, "356236": 0, "326542": 0, "334479": 0, "356239": 0, "326543": 0, "334478": 0, "356238": 0, "356233": 0, "356232": 0, "334475": 0, "356235": 0, "334474": 0, "356234": 0, "326548": 0, "309396": 0, "326549": 0, "309397": 0, "309398": 0, "309399": 0, "326544": 0, "334481": 0, "326545": 0, "334480": 0, "356240": 0, "326546": 0, "334483": 0, "309394": 0, "326547": 0, "334482": 0, "309395": 0, "309400": 0, "309401": 0, "309402": 0, "309403": 0, "402766": 9, "402767": 0, "402764": 0, "402765": 0, "402762": 0, "402763": 0, "402760": 0, "402761": 0, "416598": 0, "415318": 7, "416599": 0, "415319": 0, "416596": 0, "416597": 0, "416594": 0, "416595": 0, "402768": 0, "402769": 0, "305118": 0, "305119": 24, "416602": 0, "416603": 0, "416600": 0, "416601": 0, "305124": 0, "305125": 0, "305126": 0, "305127": 0, "305120": 0, "305121": 0, "305122": 0, "305123": 0, "339816": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "58bbcb0e-4172-41ea-b88f-ef4d87c05a8d"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });